Coronavirus disease 2019 (COVID-19) caused by a Novel Coronavirus (SARS-CoV-2)

Guidelines for case-finding, diagnosis, management and public health response in South Africa

Compiled by
the Centre for Respiratory Diseases and Meningitis and Outbreak Response, Division of Public Health Surveillance and Response, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS)

and

the National Department of Health, South Africa

Version 2.0
Guidelines writing committee (in alphabetical order):

Ahmed Bham (National Department of Health (NDoH), Emergency Medical Services (EMS))

Jinal Bhiman ((National Institute for Communicable Diseases (NICD); Centre for Respiratory Diseases and Meningitis (CRDM))

Funeka Bongweni (NDoH, Port Health)

Lucille Blumberg (NICD, Division of Public Health Surveillance and Response (DPHSR))

Cheryl Cohen (NICD, CRDM)

Linda Erasmus (NICD, DPHSR)

Jackie Kleynhans (NICD, CRDM)

Nevashan Govender (NICD, DPHSR)

Ann Mathews (NICD, DPHSR)

Kerrigan McCarthy (NICD, DPHSR)

Meredith McMorrow (U.S. Centers for Disease Control and Prevention (CDC))

Jeremy Nel (Helen Joseph Hospital)

Genevie Ntshoe (Helen Joseph Hospital)

Wayne Ramkrishna (NDoH)

Stefano Tempia (CDC)

Sibongile Walaza (NICD, CRDM)

Nicole Wolter (NICD, CRDM)

Guideline review:

This version (2.0) approved by: Cheryl Cohen and Wayne Ramkrishna  Date: 08/03/2020

Summary of changes:

<table>
<thead>
<tr>
<th>Version</th>
<th>Date reviewed</th>
<th>Reviewed by</th>
<th>Summary of changes</th>
<th>New version #</th>
</tr>
</thead>
</table>
| 1.0     | 26 February 2020 | S. Walaza and M McMorrow | • 2019 nCoV changed to COVID-19 or SARS-CoV-2 as appropriate  
• Updated case counts, etc. 
• Updated contributors  
• Updated case definition to add fever, pneumonia of unknown aetiology and countries with community transmission of COVID-19 | 1.1 |
<table>
<thead>
<tr>
<th>Section</th>
<th>Date</th>
<th>Authors</th>
<th>Updates</th>
</tr>
</thead>
</table>
| 1.1     | 8 March 2020| S. Walaza and M. McMorrow     | - Updated information on packaging of specimens-triple packaging only applicable to international specimens)  
- Additional information on differential diagnosis and treatment added |

**Disclaimer**

The information contained in this document, be it guidelines, recommendations, diagnostic algorithms or treatment regimens, are offered in this document in the public interest. To the best of the knowledge of the guideline writing team, the information contained in these guidelines is correct. Implementation of any aspect of these guidelines remains the responsibility of the implementing agency in so far as public health liability resides, or the responsibility of the individual clinician in the case of diagnosis or treatment.

Criteria for person under investigation (PUI) (Page 10):
Persons with acute respiratory illness with sudden onset of at least one of the following: cough, sore throat, shortness of breath or fever \( \geq 38^\circ C \) (measured) or history of fever (subjective) irreversible of admission status AND
In the 14 days prior to onset of symptoms, met at least one of the following epidemiological criteria:

1. Were in close contact \(^1\) with a confirmed \(^2\) or probable \(^3\) case of SARS-CoV-2 infection;
2. Had a history of travel to areas with presumed ongoing community transmission of SARS-CoV-2, i.e., China, South Korea, Japan, Iran, Hong Kong, Italy, and Taiwan (NB Affected countries will change with time, consult the NICD website for current updates);
OR
3. Worked in, or attended a health care facility where patients with SARS-CoV-2 infections were being treated;
OR
4. Admitted with severe pneumonia of unknown aetiology

\(^1\) Close contact: A person having had face-to-face contact or was in a closed environment with a COVID-19 case; this includes, amongst others, all persons living in the same household as a COVID-19 case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a COVID-19 case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the case was seated.

\(^2\) Confirmed case: A person with laboratory confirmation of SARS-CoV-2 infection, irrespective of clinical signs and symptoms.

\(^3\) Probable case: A PUI for whom testing for SARS-CoV-2 is inconclusive (the result of the test reported by the laboratory) or who tested positive on a pan-coronavirus assay.

Clinicians should also be vigilant for the possibility of atypical clinical presentations among immunocompromised patients. Consider the possibility of influenza (Northern Hemisphere season ends in April or May) and bacterial pneumonia and manage accordingly.

Infection control: Pages 10-12

Mode of transmission is typically respiratory droplet for human coronaviruses. Because patients may require aerosol-generating procedures, airborne precautions are preferred where possible.

1. Early detection is key - healthcare workers should maintain a high level of clinical suspicion
2. Patients should wear a surgical mask as soon as they are identified, and evaluated in a private room
3. Isolate PUI (ideally an airborne infection isolation room if available)
4. Use appropriate infection control for PUI
   a. Adequate standard precautions for all patients
   b. Add contact and droplet precautions for all patients
   c. Apply airborne precautions (eg. N95 mask) and eye protection must be used when performing aerosol-generating procedures
   d. If available, airborne precautions should be used at all times
   e. Limit movement of patient (e.g. use designated portable X-ray equipment)

Laboratory diagnosis and specimen collection for SARS-CoV-2 Pages 12-15, Appendices 5-8

Collect appropriate samples. Lower respiratory tract samples are preferred because the lower respiratory tract is the primary site of infection.

- **Respiratory samples** - Combined nasopharyngeal and oropharyngeal swabs in ambulatory patients and sputum and/or tracheal aspirate or bronchoalveolar lavage in patients with more severe respiratory disease. Respiratory samples are the primary method of diagnosis.
- **Serum for serological testing** - acute and convalescent samples should be submitted in addition to respiratory samples
- Place swabs together in universal transport medium (UTM), or if not available send in gel or dry, sputum and aspirates in a universal container and clotted tube for serum
- Complete person under investigation form (Appendix 8) and specimen submission form (Appendix 7)
- Transport samples at 2-8°C (in cooler box with ice packs)
- Alert NICD Hotline +27 82 883 9920

A single negative test result, especially if from upper respiratory tract specimen, does not exclude infection. Repeat sampling and testing of lower respiratory tract samples are recommended for cases with severe disease or in whom 2019-nCoV is strongly suspected.

Notification of cases and additional support: Appendix 4

- All PUI should be notified to the district provincial communicable disease control coordinator(CCDC) as per notifiable medical condition procedures (see Appendix 4 and 11 for contact details), or the NICD http://www.nicd.ac.za/notifiable-medical-conditions/
- Clinicians should discuss the case with doctor on call before collecting and sending specimens for testing at NICD Hotline: +27 82 883 9920 or +27 66 562 4021
- COVID-19 is classified as Category 1 notifiable medical condition; therefore, notification should be made immediately on identification of a case meeting case definition of person under investigation for SARS-CoV-2, a cluster of cases with severe respiratory illness with evidence of common exposure or epidemiologic link, or on receipt of a laboratory diagnosis of SARS-CoV-2 infection. Information available at http://www.nicd.ac.za/notifiable-medical-conditions/
1 Table of Contents

1 Introduction .................................................................................................................................... 7
2 Microbiology and epidemiology ..................................................................................................... 7
3 Clinical presentation and management .......................................................................................... 8
4 Surveillance and case definitions for COVID-19............................................................................ 10
  4.1 Rationale for surveillance for COVID-19 ............................................................................... 10
  4.2 Who should be tested for SARS-CoV-2? ............................................................................... 10
5 Infection control............................................................................................................................ 10
6 Laboratory diagnosis ..................................................................................................................... 12
  6.1 Who should be tested........................................................................................................... 12
  6.2 What investigations should be done .................................................................................... 12
  6.3 Specimen collection and transport ....................................................................................... 13
  6.4 Laboratory diagnostic assays and interpretation of results ................................................. 14
7 Public health response .................................................................................................................. 16
  7.1 Response to a suspected case .............................................................................................. 16
  7.2 Response to a confirmed case .............................................................................................. 16
  7.3 Contact tracing ...................................................................................................................... 16
  7.4 Management of the deceased .............................................................................................. 18
  7.5 Quarantine ............................................................................................................................ 18
8 Additional Resources .................................................................................................................... 18
9 Appendices .................................................................................................................................... 19
  9.1 Appendix 1 – process flow for detection and response to cases ......................................... 20
  9.2 Appendix 2 – roles and responsibilities of facility, district, province and national vis a vis information flow ............................................................................................................................... 21
  9.3 Appendix 3 – flow diagram for contact tracing, screening and monitoring ......................... 22
  9.4 Appendix 4 – Initial diagnosis and management of suspected case, including infection control measures ............................................................................................................................................. 23
  9.5 Appendix 5: Collection of nasopharyngeal and oropharyngeal swab and nasopharyngeal aspirate ............................................................................................................................................. 24
  9.6 Appendix 6. Procedures for submission of specimens for investigation .............................. 26
  9.7 Appendix 7 - Specimen submission form ........................................................................... 29
  9.8 Appendix 8– Person under investigation form ..................................................................... 30
  9.9 Appendix 9 – Contact tracing and contact line list ............................................................... 32
  9.10 Appendix 10 – Contact monitoring tool ................................................................................ 35
  9.11 Appendix 11 – Response to suspected case at port of entry ................................................ 36
  9.12 Appendix 12 – Guidelines for the safe handling of human remains of confirmed/suspected COVID-19 case and repatriation of human remains of confirmed/suspected COVID-19 case........ 44
9.13 Appendix 13 – Communicable Diseases Outbreak Report Format.............................................. 47
9.14 Appendix 14 – Contact details (email address and telephone) of stakeholders involved in supporting outbreak response............................................................................................................ 50
1 Introduction

On the 31 December 2019, the World Health Organization (WHO) China country office reported a cluster of pneumonia cases in Wuhan, Hubei Province of China. On 7 January 2020, the causative pathogen was identified as a novel coronavirus (SARS-CoV-2). Initially person-to-person transmission was not apparent and the majority of the cases were epidemiologically linked to a seafood, poultry and live wildlife market (Huanan Seafood Wholesale Market) in Jianghan District of Hubei Province. However, the number of cases continued to increase rapidly, and evidence of person-to-person transmission mounted in travellers diagnosed with coronavirus disease (COVID-19) who had visited Wuhan.


In the light of the transmissibility of coronaviruses, and the global experience with MERS-CoV (ongoing) and SARS in 2003 which were also caused by coronaviruses, South African authorities have compiled this guideline document to support surveillance, case finding, diagnosis, management and public health responses to cases under investigation.

2 Microbiology and epidemiology

Coronaviruses are enveloped, single-stranded positive-sense RNA viruses. The envelope of the coronaviruses is covered with club-shaped glycoproteins which look like ‘crowns’, or ‘halos’ – hence the name ‘coronavirus.’ Coronaviruses are responsible for the common cold, and usually cause self-limited upper respiratory tract infections. However, in 2003, a new coronavirus emerged leading to the SARS (severe acute respiratory syndrome) outbreak. In 2012, the Middle East respiratory syndrome (MERS) was found to be caused by a coronavirus associated with transmission from camels. Both viruses had a range of clinical presentations from mild upper respiratory tract symptoms and possibly asymptomatic infection, to severe acute respiratory syndrome leading to sepsis, multi-organ failure and death in a sizeable proportion of cases.

---

Following the identification of a cluster of pneumonia cases in Wuhan, Hubei Province of China, Chinese authorities reported on 7 January 2020 that the causative pathogen was identified as a novel coronavirus (2019-nCoV). The gene sequences were deposited in Genbank, the NIH genetic sequence database, and in the Global Initiative on Sharing All Influenza Data (GISAID) portal.

Available evidence, and experience from MERS-CoV and SARS suggests that the novel coronavirus has a possible zoonotic origin. However, human-to-human transmission of SARS-CoV-2 is now confirmed. As of 6 March 2020, over 97,000 cases and 3300 deaths have been reported from 87 countries and territories. The daily WHO situation update can be found at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. On 5 March 2020, South African Minister of Health Dr. Zweli Mkhize announced the country’s first confirmed coronavirus (COVID-19) case. The patient, a 38-year-old male in KwaZulu-Natal Province, returned to South Africa on March 1 after traveling in Italy. He developed symptoms and visited a doctor on March 3 with fever, headache, malaise, sore throat and mild cough, and subsequently self-isolated. The NICD confirmed the positive COVID-19 result and are conducting contact tracing while the patient and his doctor remain in self-isolation. A second case of COVID-19 was notified on 7 March 2020 in a fellow traveller to Italy, and a third case in the same group of travellers on 8 March 2020.

The Chinese Center for Disease Control and Prevention (China CDC) has provided epidemiological information on the first 44,672 cases detected in China3. Approximately 80% of cases were in persons aged 30-69 years, 10% in children and adults aged 0-29 years, and 10% in adults aged 70 years and older. Over 80% of cases had mild symptoms, 13.8% had severe disease, and 4.7% were critically ill. There were 1023 deaths (case-fatality rate (CFR) 2.3%). The CFR was less than 0.5% in persons aged <50 years and increased with increasing age. Co-morbid conditions were reported more commonly in fatal cases. Early estimates of transmission parameters are as follows (obtained from the first 425 confirmed cases): mean incubation period 5.2 days (95% confidence interval [CI], 4.1 to 7.0), mean serial interval 7.5 (95%CI: 5.3-19) days and basic reproductive number 2.2 (95%CI: 1.4-3.9) 4.

### 3 Clinical presentation and management

A minority, but not negligible proportion of patients have had acute, serious respiratory illness with fever, cough, shortness of breath, and breathing difficulties. Severity of illness was defined according to any of the following criteria: (i) shortness of breath; (ii) respiratory rate >30 bpm in an adult; (iii) hypoxemia; and (iv) chest X-ray with multi-lobar infiltrates or pulmonary infiltration progressing >50% within 24-48 hours. Because investigations initially focused on severe cases the severity of the infection may be overestimated among the currently known confirmed cases.

The clinical features of 41 severe cases initially detected in China have been described in detail. These patients were hospitalized in a dedicated hospital in Wuhan city. 73% were men, the median age was 49 years (IQR: 41–58 years) and 66% had been exposed to Huanan seafood market. 32% had underlying medical conditions, including diabetes (20%), hypertension (15%) and cardiovascular disease (15%). Common symptoms at onset included fever (98%), cough (76%) and myalgia or fatigue (44%). Less common symptoms were headache (8%), haemoptysis (5%) and diarrhoea (3%). Dyspnoea developed

---


in 22% of patients. The median time of dyspnoea development was 8 days (IQR: 0-13 days). 63% of patients had lymphopenia and all patients had pneumonia with abnormal findings on chest X-ray. Complications included acute respiratory distress syndrome (29%) and acute cardiac injury (19%). 32% of patients were admitted to an ICU and 15% died.

Another description of the clinical characteristic of 99 confirmed cases from China reported a median age of 55.5 years. 51% of patients had chronic diseases, 83% had fever, 82% had cough, 31% had shortness of breath, 11% had muscle ache, 9% had confusion, 8% had headache, 5% had sore throat, 4% had rhinorrhoea, 2% had chest pain, 2% had diarrhoea and 1% had nausea and vomiting. 75% of patients showed bilateral pneumonia, 14% showed multiple mottling and ground-glass opacity and 1% had pneumothorax. 17% of patients developed acute respiratory distress syndrome and of those 11% worsened rapidly and died of multiple organ failure. More clinical information is expected to emerge if cases increase, especially among patients with mild clinical presentation.

There is currently no specific treatment for disease caused by SARS-CoV-2 infection. It is important to keep a broad differential diagnosis (bacterial pneumonia, atypical bacterial pneumonia, other viral pneumonias including influenza, Pneumocystis pneumonia) until diagnosis is confirmed and to provide supportive care for a Severe Acute Respiratory Illness (SARI) or based on patient symptoms. Supportive management of SARI includes among others oxygen if required, ventilator support if required, restrictive fluid management (unless shock or acute kidney injury), and other standard supportive measures in critically ill patients.

There is early evidence that some medications used to treat HIV (lopinavir, ritonavir) may benefit patients with COVID-19 infection but further data are needed. The WHO interim clinical care guidance can be found at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance. Severe pneumonias generally require broad-spectrum antibiotics empirically and current protocols/guidelines should be followed https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506119/. Routine administration of corticosteroids should be avoided, and should only be used if, after careful consideration, risks outweigh benefits (eg. Adrenal insufficiency, COPD, Pneumocystis pneumonia). Although corticosteroids may be of benefit in severe bacterial pneumonias, they have been associated with prolonged viral shedding and increased mortality in influenza.

Atypical bacterial pneumonias are an important differential diagnosis of a viral pneumonia. Like a viral pneumonia these may have flu-like symptoms and bilateral infiltrates on X-ray. Infiltrates can appear reticulonodular/patchy, not necessarily consolidation. Empiric treatment options include a Macrolide (eg. Azithromycin) OR Quinolone (eg. Levofloxacin, moxifloxacin) OR Doxycycline.

Causes of viral pneumonias include influenza, parainfluenza, human metapneumovirus, respiratory syncytial virus, adenovirus etc. Influenza is an important differential diagnosis to consider as it is currently influenza season in the Northern hemisphere where many COVID suspects will have come from and it is potentially treatable. Empiric oseltamivir (Tamiflu) or zanamivir treatment should be considered in patients with an influenza-like illness who are severely ill or are at high risk for complications (pregnant women, HIV-infected patients, patients with asthma/COPD etc). Treatment should be started as soon as possible, with best chance of benefit within 48 hours of symptom onset. Oseltamivir 75mg po 12-hourly for 5 days. For more information; see NICD Influenza Guidelines 5

---

Pneumocystis jirovecii pneumonia should be considered in patients who are significantly immunocompromised: HIV-positive with CD4<200, chronic systemic steroid use, chemotherapy, transplant patients, etc.) with diffuse bilateral infiltrates on X-ray (often mid to lower zone predominance) and hypoxemia at rest (or with exertion in mild cases). Consider empiric treatment as per local guidelines if these criteria are met.

4 Surveillance and case definitions for COVID-19

4.1 Rationale for surveillance for COVID-19

Surveillance for COVID-19 is essential to permit early recognition of suspected cases, early diagnosis, containment and prevention of further cases. Surveillance should be conducted by all clinicians and health facilities. Staff should be aware of the surveillance case definitions, and implement routine screening where appropriate (e.g. on returning travellers from affected areas).

4.2 Who should be tested for SARS-CoV-2?

Surveillance case definitions for persons under investigation (PUI) who should be tested for COVID-19

Persons with acute respiratory illness with sudden onset of at least one of the following: cough, sore throat, shortness of breath or fever [≥ 38°C (measured) or history of fever (subjective)] irrespective of admission status AND

In the 14 days prior to onset of symptoms, met at least one of the following epidemiological criteria:

- Were in close contact with a confirmed or probable case of SARS-CoV-2 infection;

OR

- Had a history of travel to areas with presumed ongoing community transmission of 2019-nCoV; i.e. China, South Korea, Japan, Iran, Hong Kong, Italy, and Taiwan (NB affected countries will change with time, consult the NICD website for current updates);

OR

- Worked in or attended a healthcare facility where patients with SARS-CoV-2 infections were being treated;

OR

- Admitted with severe pneumonia of unknown aetiology

A confirmed case: is a person with a laboratory-confirmation of infection with SARS-CoV-2.

A probable case: A PUI for whom testing for SARS-CoV-2 is inconclusive (the result of the test reported by the laboratory) or who tested positive on a pan-coronavirus assay.

A close contact is defined in section 7.3. (contact tracing)

5 Infection control

Ongoing investigations are needed to more fully understand the transmissibility of SARS-CoV-2, but person-to-person spread is occurring and person-to-person and nosocomial transmission was common with MERS-CoV and SARS. The main route of transmission is through contact and respiratory droplets. Airborne transmission has not been proven. The virus is excreted in stool so faeco-oral transmission may be possible. Triage, early recognition and isolation of patients with suspected 2019-nCoV is essential to prevent or limit transmission in healthcare settings.

Based on currently available data, symptomatic cases seem to be the main driver of transmission. WHO is aware of possible transmission of SARS-CoV-2 from infected people prior to developing
symptoms. Further information is needed to better understand how transmission may have occurred in these few instances. Transmission from an asymptomatic person is very rare with other coronaviruses. Persons who are symptomatic will spread the virus more readily through coughing and sneezing.

• Standard infection-control measures should be applied for all patients with symptoms of acute respiratory infection including:
  o hand and respiratory hygiene
  o use of appropriate personal protective equipment
  o environmental and disinfection procedures should be applied

• For PUI:
  • place a surgical/medical mask over the patients’ nose and mouth and evaluate in a private room with the door closed.
  • implement additional contact and droplet precautions
  • use airborne precautions (eg. N95 mask) and eye protection when performing aerosol-generating procedures.
  • if available, airborne precautions should be used at all times.

Healthcare workers are advised to refer to the WHO interim guidance on infection prevention and control during health care for suspected cases of COVID-19. This can be accessed on the WHO website: https://www.who.int/docs/default-source/coronaviruse/20200126-ncov-ipc-during-health-care.pdf?sfvrsn=69e588ce_1&download=true and will be updated as additional information becomes available.

Key contact and droplet precautions include the following:
• isolate the patient (ideally an airborne infection isolation room if available, otherwise adequately ventilated single rooms)
• place patient in a separate room
• healthcare workers to use a medical (surgical/medical) mask and eye (goggles) or facial protection (face shield)
• healthcare workers should wear a clean, non-sterile, long-sleeved gown and use gloves
• healthcare workers should not touch their eyes, nose or mouth with potentially contaminated gloves or bare hands
• limit movement of patient (eg. use designated portable X-ray equipment)
• routinely clean and disinfect surfaces with which the patient is in contact
• limit the number of healthcare workers, family and visitors in contact with suspected or confirmed cases

Additional precautions to be used during aerosol-generating procedures include:
• performing procedures in an adequately ventilated room
• minimising respirator face-seal leakage to fully protect the worker from exposure to aerosolized infectious droplets when using particulate respirators e.g. N95 mask
• eye protection (goggles or face shield) to protect the eyes from respiratory splash or spray
• contact protection (non-sterile, long-sleeved gown and gloves)
Patients with suspected COVID-19 cared for in the home environment

Given the limited knowledge of the disease caused by and transmission of SARS-CoV-2, WHO currently recommends that suspected cases of COVID-19 should be isolated and monitored in a hospital setting. However, under certain circumstances, patients with suspected COVID-19 with mild symptoms and no underlying or immunocompromising conditions may be cared for/isolated in the home environment.


6 Laboratory diagnosis

6.1 Who should be tested

Only PUI for COVID-19 should be tested. Rapid collection, transport and testing of appropriate specimens from PUI is a priority. Patients should be managed as potentially infected when the clinical and epidemiological data strongly suggest SARS-CoV-2 infection.

Clinical specimens should be collected as soon as possible after onset of symptoms, ideally within 7 days. If patient presents ≥7 days from symptom onset and is still symptomatic, respiratory samples, especially lower respiratory samples and a serum sample should still be collected.

6.2 What investigations should be done

- From the moment that COVID-19 is considered as a diagnostic possibility, persons under investigation should be isolated, and infection control measures as described above should be implemented.
- For PUI, appropriate specimens should be collected and transported urgently (same day as collection) for SARS-CoV-2 testing.
- PUI with severe illness should also undergo routinely available laboratory tests as clinically indicated according to local management guidelines for community-acquired pneumonia to determine the presence of other potential primary aetiologies of pneumonia (e.g Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, Mycobacterium tuberculosis and respiratory viruses including influenza, and respiratory syncytial virus (RSV)). These investigations include at least the following
  - Full blood count
  - Blood cultures
  - Lower respiratory tract specimens
  - Nasopharyngeal swabs or aspirates and oropharyngeal swabs for detection of viral and atypical pathogens
  - Chest radiography
  - Sputum for Mycobacterium tuberculosis microscopy and/or molecular detection
- As the role of co-infections is not yet clearly understood, identification of a conventional respiratory pathogen does not rule out SARS-CoV-2 infection.
6.3 Specimen collection and transport

- Infection prevention and control guidelines, including adequate PPE, must be followed during specimen collection, and all specimens handled as potentially infectious.

- Lower respiratory tract samples are the preferred specimen type because the lower respiratory tract is the primary site of infection and they are likely to contain the highest viral loads (based on experience with MERS-CoV) and therefore have a better yield. However, collection of all three specimen types (lower respiratory, upper respiratory and serum) for SARS-CoV-2 testing is recommended (Table 1):

  1. Upper respiratory tract specimens - combined nasopharyngeal (NP) and oropharyngeal (OP) swabs in universal transport medium (UTM, or if not available may be sent in gel or dry. Nasopharyngeal swabs must be collected from the nasopharynx and not from the nostril (See appendix 5 on how to collect NP and OP samples). Nasopharyngeal and oropharyngeal swabs should be placed together in the same UTM tube or may be submitted in gel or dry if UTM not available.

  2. Lower respiratory tract specimens (hospitalised/severe cases) – sputum (expectorated or induced), bronchoalveolar lavage, endotracheal aspirate should be submitted in clean universal containers.

  3. Serum - Paired serum samples should be collected; acute (first week of illness) and convalescent (3-4 weeks). Serological testing, in addition to respiratory samples, may support the diagnosis of COVID-19 once serologic tests become available.

- Clinical specimens from suspected or confirmed cases must be shipped to NICD by trained personnel according to the local or international regulations for the transport of dangerous goods (UN3373, Biological Substance Category B infectious substances). See Table 1 for specimen transport conditions. Viral cultures or isolates should be transported as Category A, UN2814, “infectious substance affecting humans”.

- Appendix 6 describes detailed procedures for submission of specimens (local and international) to NICD for persons under investigation

- A completed specimen submission form (Appendix 7) must be submitted to the laboratory together with specimens for SARS-CoV-2 testing.

Table 1 lists the type of specimens that can be collected for testing for SARS-CoV-2.

Table 1. Type of specimens that can be collected for SARS-CoV-2/COVID-19 diagnostics and the transport requirements of these specimens

<table>
<thead>
<tr>
<th>Specimen type</th>
<th>Collection materials</th>
<th>Storage and transportation</th>
<th>Dangerous goods shipping category</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOR SYMPTOMATIC PATIENTS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sputum*</td>
<td>Deep cough sputum in sterile leak proof container</td>
<td>Refrigerate and ship at 2-8 °C up to 48 hrs, if &gt;48 hrs freeze at -70°C and ship on dry ice</td>
<td>Biological substance, Category B</td>
<td>The preferred sample but need to ensure the material is from the lower respiratory tract</td>
</tr>
<tr>
<td>Bronchoalveolar lavage*</td>
<td>2-3 ml in sterile leak proof container</td>
<td>Refrigerate and ship at 2-8 °C up to 48 hrs, if &gt;48 hrs freeze at -70°C and ship on dry ice</td>
<td>Biological substance, Category B</td>
<td>There may be some dilution of virus but still a worthwhile specimen</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>(Endo)tracheal or nasopharyngeal aspirate*</td>
<td>2-3 ml in sterile leak proof container</td>
<td>Refrigerate and ship at 2-8 °C up to 48 hrs, if &gt;48 hrs freeze at -70°C and ship on dry ice</td>
<td>Biological substance, Category B</td>
<td>Biological substance, Category B</td>
</tr>
<tr>
<td>Nasopharyngeal and oropharyngeal swab</td>
<td>Dacron or nylon flocked swab in Universal Transport Medium (UTM) or gel (or dry if neither available) in a sterile leak proof container</td>
<td>Refrigerate at 2-8 °C up to 5 days, if &gt;5 days freeze at -70°C and ship on dry ice</td>
<td>Biological substance, Category B</td>
<td>Biological substance, Category B</td>
</tr>
</tbody>
</table>
| Serum | Serum separator tube** | Store upright for at least 30 minutes after collection. a Refrigerate and ship at 2-8 °C within 5 days | Biological substance, Category B | Collect paired samples: 
• Acute – first week of illness 
• Convalescent – 3-4 weeks later |
| Lung tissue from biopsy or autopsy | Sterile container with saline | Refrigerate and ship at 2-8 °C up to 24 hrs, if >24 hrs freeze at -70°C and ship on dry ice | Biological substance, Category B | Biological substance, Category B |

* Aerosol-generating procedures may pose an infection risk for health care workers. ** Children and adults: collect 1 tube (5-10 ml) of whole blood in a serum separator tube. Infant: a minimum of 1 ml in a serum separator tube.

### 6.4 Laboratory diagnostic assays and interpretation of results

Routine confirmation of cases of COVID-19 is based on amplification and detection of unique SARS-CoV-2 viral nucleic acid sequences by real-time reverse-transcription polymerase chain reaction (rRT-PCR), with confirmation by nucleic acid sequencing when necessary.7

Currently, the NICD offers testing for SARS-CoV-2 using the Charite Institute rRT-PCR assay. The protocol for testing is based on a method described by Corman et al, 2020.8 Testing for SARS-CoV-2 must be performed in appropriately equipped laboratories by staff trained in the relevant technical and safety procedures. Initial processing of specimens (before inactivation) should be done in a biological safety cabinet. Molecular testing should be conducted in an ABL-2 laboratory. Viral culture and isolation should only be performed by properly trained and competent personnel in a BS-3 laboratory. Appropriate PPE must be worn by all laboratory personnel handling SARS-CoV-2 specimens.

A negative result does not rule out the possibility of a SARS-CoV-2 infection. A number of factors could lead to a false-negative result including:

- Poor specimen quality
- The specimen was collected late or very early in the illness
- The specimen was not handled and shipped appropriately, e.g. the cold chain of specimens was not properly maintained throughout the process i.e. from the point of collection up until receipt and processing
- Technical reasons inherent in the test, e.g. virus mutation or PCR inhibition.

---


If negative results are obtained from patients with a high index of suspicion for SARS-CoV-2 infection, especially when only upper respiratory tract samples were collected, additional specimens, including lower respiratory samples should be collected and tested.

Figure 1 illustrates the laboratory algorithm followed for testing of specimens collected from a suspected COVID-19 case.

![Algorithm for testing persons under investigation for SARS-CoV-2 by rRT-PCR and sequencing](image)

**Figure 1:** Algorithm for testing persons under investigation for SARS-CoV-2 by rRT-PCR and sequencing

The laboratory turnaround time (TAT) for SARS-CoV-2 testing is 24 hours from time of specimen receipt in the NICD laboratory. Where possible, a specimen that tests positive for SARS-CoV-2 will be further characterised by viral culture and whole genome sequencing.
7 Public health response
The detection of a case of COVID-19 constitutes a public health emergency and a risk to the safety of
the patient, their contacts including health care workers, and more broadly, the wellbeing of the
South African community. Even at the time the decision is made to test a patient for COVID-19,
consideration must be made of the public health response.

The South African National Department of Health, the NICD and provincial health departments have
structures for responding to outbreaks of communicable diseases, and these have been activated to
assist with preparedness activities.

7.1 Response to a suspected case
See flow diagram in appendix 1, 2 and 4 for management of PUI.

7.2 Response to a confirmed case

- Any person who has had close contact with a confirmed case while the confirmed case was ill
  or in the 7 days preceding illness onset should be carefully monitored (at home) for the
  appearance of respiratory symptoms.
- If symptoms develop within the first 14 days following the contact, the individual should be
  considered a PUI regardless of the severity of illness and investigated accordingly.
- Close contacts who are ill and do not require hospitalisation for medical reasons may be cared
  for and isolated in their home while being evaluated for SARS-CoV-2 infection. (Isolation is
defined as the separation or restriction of activities of an ill person with a contagious disease
from those who are well).

7.3 Contact tracing

- A flow diagram for contact tracing is in Appendix 3. A contact line list (Appendix 9) should be
  completed for each person under investigation at time of sample collection and completion
  of the investigation form by the facility infection control focal point, attending clinician or
  designated port health officer. If the form cannot be completed at this time, the district or
  provincial CDC will complete the form when notified of the case. A copy of this form should
  be submitted to ncov@nicd.ac.za.

- Details of close contacts from the day of symptom onset will be collected on the contact line
  list.

- A close contact is defined as:
  - A person having had face-to-face contact (≤2 metres) or was in a closed
    environment with a COVID-19 case; this includes, amongst others, all persons living
    in the same household as a COVID-19 case and, people working closely in the same
    environment as a case,
  - A healthcare worker or other person providing direct care for a COVID-19 case while
    not wearing recommended personal protective equipment or PPE (e.g., gowns,
gloves, NIOSH-certified disposable N95 respirator, eye protection),
  - A contact in an aircraft sitting within two seats (in any direction) of the COVID-19
    case, travel companions or persons providing care, and crew members serving in the
    section of the aircraft where the index case was seated [1] (if severity of symptoms
    or movement of the case indicate more extensive exposure, passengers seated in
If laboratory testing confirms SARS-CoV-2 infection, the provincial CDCC will be requested to use the contact line list to call each contact to complete the contact demographic section on the contact monitoring form. Once details are completed, forms are to be emailed to ncov@nicd.ac.za.

Forms will be captured on the COVID-19 contact database at NICD.

A thermometer will be issued to each contact if they do not have one. Close contacts will be asked to self-quarantine themselves at home for 14 days since last exposure to the confirmed COVID-19 case.

Close contacts will be monitored telephonically by the NICD call centre personnel for 14 days post last exposure to the confirmed case using the symptom monitoring tool (Appendix 10) and captured directly to the database. If at any point during the monitoring period the contact becomes unreachable for more than 24 hours, the provincial CDCC team will do a home visit. For contacts who are not able to perform daily temperature measurements at home, daily home visits will be conducted by provincial CDCC team.

Monitoring of close contacts may switch from telephonic monitoring to self-monitoring dependant on the number of contacts to be followed up.

Close contacts under monitoring should be advised to:

- Remain at home (CDCC /NICD will provide an official letter for employment or education facilities)
- Avoid unnecessary social contact
- Avoid travel
- Remain reachable for monitoring

Should a contact develop symptoms, the provincial CDCC should be informed by NICD. Arrangements will be made by CDCC for a health care worker to visit the patient in their home on the same day to collect a specimen and to complete the required documentation. Appropriate PPE should be used (e.g., gowns, gloves, surgical mask or NIOSH-certified disposable N95 respirator, eye protection). If a healthcare worker is not available, the patient will be requested to visit their nearest healthcare facility to have a specimen collected.

The CDCC should inform the healthcare facility of the incoming patient in order for the healthcare facility to use appropriate infection prevention and control (IPC) measures.

Monitoring of close contacts may switch from telephonic monitoring to self-monitoring dependant on the number of contacts to be followed up.

Individuals not meeting the definition of a close contact but with possible exposure should be informed to contact their healthcare practitioner if any symptoms develop within 14 days since exposure to the confirmed COVID-19 case.

Healthcare workers with occupational exposure
• Lists of healthcare workers with occupation exposure should be compiled by the health facility

• They should be actively monitored for symptoms and rapidly isolated and tested should symptoms develop

7.3.1 Data management
All contact line lists and symptom monitoring forms with completed demographic information should be forwarded to ncov@nicd.ac.za for capturing at NICD. Symptom monitoring should be captured directly to database, by NICD call-centre personnel.

7.4 Management of the deceased
• All attempts should be made to confirm the diagnosis in persons who are close contacts who die. Post mortem nasopharyngeal swabs, and if possible, bronchial washings may be taken. Contact and droplet precautions should be used.

7.5 Quarantine
Quarantine entails separating asymptomatic individuals potentially exposed to a disease from non-exposed individuals. Quarantine is to be distinguished from isolation, which is the act of separating a sick individual with a contagious disease from healthy individuals without that contagious disease. Quarantine procedures can be effective in limiting and slowing the introduction of a novel pathogen into a population, but may entail the use of considerable resources and may infringe on the rights of members of society. Quarantine may be voluntary (e.g. asking contacts of infectious cases to stay at home for 14 days) or involuntary (i.e. using legal powers to enforce quarantine against a person’s will). Quarantine may take place in the home (e.g. asking contacts of infectious cases to stay at home for 14 days) or in a designated facility. Depending on level of risk of the exposure different levels of quarantine will be employed, for an example if a person comes back from Wuhan, voluntary quarantine at home will be recommended. Whereas, if health worker not wearing appropriate PEP is exposed to a confirmed case, the health worker would be allowed to work and self-quarantine after hours. Quarantine may be applied at the individual level or to a group or community of exposed persons. Asymptomatic contacts will be voluntarily quarantined at home.

8 Additional Resources
• NICD website on 2019-nCoV: http://www.nicd.ac.za/diseases-a-z-index/covid-19/
• Daily WHO situation update: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
• WHO interim guidance on infection prevention and control during health care for suspected cases of 2019-nCoV: https://www.who.int/docs/default-source/冠状病毒/20200126-ncov-ipc-during-health-care.pdf?sfvrsn=69e588ce_1&download=true
• WHO Coronavirus Information Page: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
9 Appendices
9.1 Appendix 1 – process flow for detection and response to cases

DETECTION AND REPORTING OF PERSON UNDER INVESTIGATION FOR COVID-19

- The case definition must be strictly adhered to
- For any person under investigation, isolate the patient in a suitable room/unit for assessment, apply IPC measures, contact NICD Hotline to confirm if case definition is met and if sample collection is warranted.
- If so, collect specimen and complete accompanying documentation (Appendix 7).
- Guidelines for the collection and submission of specimens to NICD available on NICD website: http://www.nicd.ac.za/diseases-a-z-index/covid-19/ (see quick reference for healthcare workers) or appendix 5 and 6
- The facility IPC focal point, clinician or designated port health officer should complete the case investigation form and contact line list (Appendix 8, 9), forward the forms to the Provincial Communicable Disease Control and ncov@nicd.ac.za.
- All suspected cases who meet the case definition should be notified as Class 1 notifiable medical condition under “Respiratory Disease caused by a novel respiratory pathogen”

MEDICAL MANAGEMENT

- For all cases irrespective of symptom severity, isolate the patient and apply infection precautions in accordance with site-specific standard operating procedures for this purpose. When the number of confirmed cases becomes too high, mild cases may be managed at home (self-isolation)

TRANSPORT AND/OR REFERAL OF PERSON UNDER INVESTIGATION FOR COVID-19 TO HOSPITAL

- If facility is able to provide required clinical care for patient in isolation, referral or transfer is not indicated. If facility cannot offer required care, transfer or referral should be discussed by calling NICD Hotline.
- Transfer of patients from port of entry to healthcare facilities to be discussed with NICD Hotline, EMS will facilitate the transport arrangements.

Laboratory testing excludes SARS-CoV-2

Laboratory testing confirms SARS-CoV-2

MULTI-DISCIPLINARY PUBLIC HEALTH RESPONSE

- NICD report back case was confirmed to healthcare facility, clinician, patient, provincial CDC
- Provincial CDC/designated NICD personnel to perform contact tracing as described in appendix 3
- Collate information and share reports with key stakeholders.
- Handling of mortal remains of a confirmed or probable case must be in accordance with guidelines
- Efficient and transparent communication with the media (press release/briefs) must be provided
- Writing of reports e.g. daily updates, preliminary and final (Appendix 13)

Contacts and details:
Consultant on call for Infectious Diseases
According to site-specific protocol
NICD Hotline
082-883-9920
066-562-4021
National Health Operations Centre
012-395-9636/37

Contacts and details: see Appendix 14
National and Provincial CDC
Provincial Port Health
EMS
9.2 Appendix 2 – roles and responsibilities of facility, district, province and national vis a vis information flow

Health Facility

- Clinician suspects a case of EVD/VHF at health facility
  - Communicates this information to site-specific contacts (as per site-specific procedure) and NCD Hotline

Infection control nurse

- Immediately notifies District Level
- Immediately fills in a notification form

District Outbreak Response Team Chairperson

- Immediately notifies Province
- Captures notification on an electronic system

District Outbreak Response Team

- Surveillance
- Environmental Health/Port Health
- Health promotion, School Health
- Communicable Disease Control
- Animal Health
- Local laboratories
- Other sectors

Local Laboratory

- Liaises with NHC/NCD for EVD/VHF specific investigations
- Performs routine blood testing as per protocol for suspected VHF cases

Province

- Provincial Outbreak Response Team Chairperson
  - Immediately notifies National Level

Provincial Outbreak Response Team

- Environmental Health/Port Health
- Surveillance
- Health promotion, School Health
- Communicable Disease Control
- Laboratory
- Animal Health
- Other Sectors

National

- National Outbreak Response Team Chairperson
  - Immediately notifiesWHO/Level

National Multi-sectoral Outbreak Response Team (MNORT)

- Surveillance
- Environmental Health/Port Health
- Health promotion, School Health
- Communicable Disease Control
- Laboratory/NCD
- Animal Health, and other sectors

National Institute for Communicable Diseases (NICD)

Feedback
9.3 Appendix 3 – flow diagram for contact tracing, screening and monitoring

**Screening individual at risk**
- Initial screening of persons listed on contact line list (Appendix 9)

**Evaluating and quantifying risk**
- Risk assessment (Apply definition of contact)
  - Close* contact
  - Casual** contact
  - Not a contact
    - Self-quarantine
    - Avoid nonessential contact
    - No monitoring required
      - Stop

**Monitoring those at risk**
- Monitoring required for 14 days since date of last contact with confirmed case
  - Active telephonic monitoring***
  - Self-monitoring***

**Development of symptoms and management thereafter**
- Symptoms develop
- No symptoms develop
  - Stop

**Is this a case?**
- Case investigation (Testing, PUI form, contact form, complete Appendix 7-9)
  - Case
    - Contact tracing
  - Not a case
    - Stop

* Close contact: A person having had face-to-face contact (42 metres) or work in a closed environment with a COVID-19 case; this includes, amongst others, all persons living in the same household as a COVID-19 case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a COVID-19 case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH certified disposable N95 respirator, eye protection). A contact is an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated.

**Casual contact:** Anyone not meeting the definition for a close contact but with possible exposure.

**Monitoring methods:** Active-telephonic monitoring: NCO call centre will phone person who is home quarantined each day for a symptom report; Self-monitoring: person to consult healthcare practitioner in event of symptoms development.
9.4 Appendix 4 – Initial diagnosis and management of suspected case, including infection control measures

**Coronavirus disease 2019 (COVID-19) process flow for use in healthcare facilities**

*Close contact: A person having had face-to-face contact (≤2 metres) or was in a closed environment with a COVID-19 case; this includes, amongst others, all persons living in the same household as a COVID-19 case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a COVID-19 case, while wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, N95 respirator eye protection). A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated.*

---

**Guidelines for COVID-19 V2.0 8-03-2020**

Page 23 of 53
9.5 Appendix 5: Collection of nasopharyngeal and oropharyngeal swab and nasopharyngeal aspirate

Type of swabs

Only nylon or rayon flocked nasopharyngeal and oropharyngeal swabs with perforated, flexible plastic shaft must be used for collection of specimens. There is evidence to suggest some benefit to using flocked swabs for recovery of pathogens over other types. An appropriate size of the nasopharyngeal swab should be used, paediatric swab for children and adult swab for older children and adults. Cotton-tipped, calcium alginate swabs or swabs with wooden shafts should not be used as residues present in these materials may inhibit PCR assays.

Collecting the nasopharyngeal swab

- Gently insert nasopharyngeal flocked swab into the nostril aiming backwards, along the floor of the nasal cavity, until the nasopharynx is reached. Be careful not to insert swab upwards. If resistance is encountered during insertion of the swab, remove it and try the other nostril. The distance from the nose to the ear gives an estimate of the distance the swab should be inserted
- Gently rotate the swab and hold in place for a few seconds
- Slowly withdraw swab
- Unscrew and remove the cap from the tube with transport medium.
- Insert the swab directly into a vial containing universal transport medium (UTM)
- Break plastic shaft at the break point so that it can fit in the universal transport medium tube
- Close the tube with the lid
- Refrigerate at 2-8 °C

Collecting oropharyngeal swab (OPS)

- Keeping the same pair of gloves on, and holding the UTM with the nasopharyngeal swab in, take a second flocked swab and open it at the plastic shaft
- Ask the patient to tilt their head back and open mouth wide
- Hold the tongue down with a tongue depressor
- Have the patient say “aahh” to elevate the uvula
- Swab each tonsil first, then the posterior pharynx in a “figure 8” movement
- Avoid swabbing the soft palate and do not touch the tongue with the swab tip as this procedure can induce the gag reflex.
- Insert the swab directly into the same UTM vial containing the nasopharyngeal swab
- Break plastic shaft at the break point so that it can fit in the universal transport medium tube
- Close the tube with the lid
- Refrigerate at 2-8 °C
Figure 1: How to collect a nasopharyngeal swab (left) and oropharyngeal swab (right)

**Nasopharyngeal aspirates**

- Fill syringe with 2-3 ml saline; attach catheter tubing to syringe tip
- Slowly insert the catheter into one nostril until the pharyngeal wall is reached
- Quickly inject saline into nostril and then aspirate the recoverable nasopharyngeal specimen
- Withdraw the catheter under suction, being careful not to touch the tip
- Inject the aspirated fluid into a labelled sterile specimen container/ universal transport medium
- Refrigerate at 2-8 °C

Figure 2: Flocked swab and Universal Transport Medium
9.6 Appendix 6. Procedures for submission of specimens for investigation

Step 1: Report the PUI to the NICD to allow a risk assessment to be carried out and guide laboratory testing

- Contact the NICD Hotline +27 82 883 9920
- The test will be free of charge for patients meeting the case definitions above

Step 2: Complete the person under investigation form and specimen submission form

- Fully complete the person under investigation form http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/
- Fully complete the specimen submission form for each specimen submitted for testing http://www.nicd.ac.za/diseases-a-z-index/novel-coronavirus-infection/. For the “Test requested” section, select “Other” and specify “Novel coronavirus” or “SARS-CoV-2”.

Step 3: Submit specimens for specialized laboratory investigation

- Each specimen should be clearly labelled with the patient name, date of birth and sample type.
- The specimens should be stored and shipped at 2-8°C (cooler box with ice packs). Specimens should be packaged in accordance with the guidelines for the transport of biological goods and transported directly and urgently.
- Transport specimens to NICD on same day as specimen collection.
- Please mark for attention of:

  Suspected novel coronavirus (COVID-19) CRDM
  NHLS/NICD
  Centre for Respiratory Disease and Meningitis (CRDM)
  Lower North Wing, SAVP building
  1 Modderfontein Rd, Sandringham, Johannesburg, 2131
  South Africa

- Please notify by email the CRDM staff below of any pending shipments:
  - Linda de Gouveia lindad@nicd.ac.za (011-555-0327) or
  - Amelia Buys ameliab@nicd.ac.za (011-386-6373) or
  - Cardia Fourie cardiaf@nicd.ac.za (011-386-6373)

- Ensure that the completed (i) specimen submission form and (ii) person under investigation form accompanies the specimens
- Avoid repeated freezing and thawing of specimens

- Packaging and transport of samples to NICD

Samples referred from local (same province) or national (different province) NHLS and private laboratories to NICD
Laboratories should follow their local guidelines/transport SOPs for sample packaging and make use of usual overnight regional courier services to ship samples to NICD.

- Contact CRDM for assistance if transport system is not available
- Patient specimens from suspected for confirmed COVID-19 cases should be transported as Biological Substance Category B.
- For local and national shipments, specimens should be placed in a secondary container (Ziploc bag), to minimise potential for spill, and transported in a clearly marked cooler box with ice packs.

**International transport of clinical samples from suspected or confirmed cases:**

The parcel should bear the appropriate outer warnings that it contains biohazardous material. If transported by air, IATA regulations (UN3373, Biological Substance, Category B) must be followed and appropriate labelling applied (refer to www.iata.org.). In addition to completing an ordinary air waybill for parcels sent by air, it is necessary to complete a shipper's declaration for dangerous goods (refer to www.iata.org or your courier company). The principle of triple layer packaging and IATA regulations must be followed (Figure 1). UN/WHO approved shipping containers for hazardous specimens are commercially available, e.g. SAF-T-PAK® (www.saftpak.com) or PATHOPAK® (www.intelsius.com).

![Figure 1. Example of the triple packaging system for the packing and labelling of Category B Biological substances for international shipment of clinical specimens.](image-url)
It is required that designated staff members per site are trained by approved provider in the 
packaging and transport of dangerous goods. The IATA of WHO websites may be consulted for 
international regulations and guidelines in this regard. **Primary specimen containers** (properly 
labelled) should be wrapped in sufficient absorbent material (paper towels or tissues) to absorb the 
entire contents in the event of leakage. The wrapped primary containers must be placed in durable, 
leak-proof **secondary containers** such as several layers of sealed plastic bags or, preferably, rigid 
screw-cap metal, plastic or similar containers (suitable containers are usually available from hospital 
dispensaries). The secondary container should be taped closed to prevent leakage. The secondary 
containers and data forms, sealed separately in plastic, must then be placed in a **rigid outer (tertiary) 
container** such as a fibre carton or polystyrene cold box with cold packs. The outer wrapping should 
be addressed to:

**NHLS/NICD**
Centre for Respiratory Disease and Meningitis (CRDM)
Lower North Wing, SAVP building
1 Modderfontein Rd, Sandringham, Johannesburg, 2131
South Africa
### 9.7 Appendix 7 - Specimen submission form

The pdf can be downloaded at [http://www.nicd.ac.za/diseases-a-z-index/covid-19/](http://www.nicd.ac.za/diseases-a-z-index/covid-19/)

---

**Centre for Respiratory Diseases and Meningitis**

---

#### Specimen Submission form

**Patient Information**

<table>
<thead>
<tr>
<th>Identifier or Hospital no</th>
<th>Surname</th>
<th>First name</th>
<th>Age/Date of birth</th>
<th>Gender</th>
<th>Facility/Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Submitter Information (contact person for results)**

<table>
<thead>
<tr>
<th>CRDM unique no</th>
<th>CRDM lab no</th>
<th>Trak no</th>
<th>Date received</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Specimen Details**

**Specimen collection date:**

**Specimen type:**

- [ ] Combined NP/OP swab
- [ ] Nasopharyngeal (NP) aspirate
- [ ] Nasal swab
- [ ] Bronchial lavage (BAL)
- [ ] Sputum
- [ ] Oropharyngeal (OP) swab
- [ ] CSF
- [ ] Tracheal aspirate (TA)
- [ ] Blood culture
- [ ] Serum
- [ ] Whole blood
- [ ] Other, specify:  

---

**Laboratory Test Details**

*Please consult with CRDM if testing other than influenza, RSV or B. pertussis is required.*

*Refer to page 3 for test panel details.*

**Tests requested:**

- [ ] Avian influenza
- [ ] Bovine influenza
- [ ] Influenza A/H3N2
- [ ] Influenza A/H1N1
- [ ] Influenza B
- [ ] Respiratory panel (bacterial & viral)
- [ ] Respiratory panel (bacterial & viral)
- [ ] Group A streptococcus
- [ ] Group B streptococcus
- [ ] Hospital-acquired pneumonia (bacteria)
- [ ] Community-acquired pneumonia (bacteria)
- [ ] Other, specify:  

---

**Clinical Presentation and Outcome**

**Clinical presentation:***

- [ ] Acute rheumatic fever
- [ ] Diptheria
- [ ] Meningococcal disease
- [ ] Lower respiratory tract infection
- [ ] Meningitis
- [ ] Other, specify:  

**Symptoms:**

- [ ] Fever (≥38°C)
- [ ] Sore throat
- [ ] Cough
- [ ] Headache
- [ ] Siff neck
- [ ] Shortness of breath
- [ ] Vomiting
- [ ] Diarrhoea
- [ ] Paroxysmal cough/inspiratory whoop
- [ ] Other, specify:  

**Underlying Risk Factors:**

- [ ] Asthma
- [ ] Chronic Lung Disease
- [ ] Diabetes
- [ ] HIV
- [ ] Pregnancy
- [ ] TB
- [ ] Heart Disease
- [ ] Other, specify:  

**Hospitalisation:**

- [ ] Outpatient
- [ ] Inpatient — not admitted ICU
- [ ] Inpatient — admitted to ICU
- [ ] Unknown

**Outcome:**

- [ ] Still hospitalised
- [ ] Survived
- [ ] Died
- [ ] Unknown

---

**Exposure History**

**Did the patient travel in the 14 days prior to symptom onset?**

- [ ] Yes
- [ ] No
- [ ] Unknown

**Area/Country travelled to**

<table>
<thead>
<tr>
<th>Date of travel to this area</th>
<th>Date of travel from this area</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Did the patient have animal contact in the 14 days prior to symptom onset?**

- [ ] Yes
- [ ] No
- [ ] Unknown

**Animal type**

- [ ] Swine
- [ ] Wildbirds
- [ ] Poultry (eg. chickens, ostrich, ducks)
- [ ] Other, specify:  

---

Tel: +27 (0)11 555 0315 | NICD Hotline: 082 853 5920

Email: fmicd@nicd.ac.za | NICD CyberSecurity: NICD.AC.ZA

Please attach any relevant information.

CRDM Specimen Submission Form V3 Feb 2020

**Date entered:**

**Initials:**
## 9.8 Appendix 8– Person under investigation form

PDF version at: [http://www.nicd.ac.za/diseases-a-z-index/covid-19/](http://www.nicd.ac.za/diseases-a-z-index/covid-19/)

**Person under investigation (PUI) form for coronavirus disease 2019 (COVID-19):**
Request for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing

**Internal use**

**ORIM unique no:** ________________

**Today’s date:** __DD/MM/YYYY__ __Form completed by (Name, Surname):______ __Contact number(s):______

All suspected COVID-19 cases are Category 1 notifiable medical conditions under "Respiratory disease caused by a novel respiratory pathogen". Notify as per NMC procedures. If using NMC app provide case ID indicated on alert email.

**Case ID:** ________________

**Is this a:** New clinical query ☐ Contact of a known case ☐ Known case first name: ________________

**If contact of a known case, provide case details:**

Known case surname: ________________ Known case DOB: __DD/MM/YYYY__

**Detected at point of entry?**

☐ Yes, date: __DD/MM/YYYY__ ☐ No ☐ Unknown __Please specify the point of entry:______________

<table>
<thead>
<tr>
<th><strong>PATIENT DETAILS</strong></th>
<th><strong>DOCTOR’S DETAILS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient hospital number (if available):</strong></td>
<td></td>
</tr>
<tr>
<td><strong>First name:</strong></td>
<td><strong>First name:</strong></td>
</tr>
<tr>
<td><strong>DOB:</strong> <strong>DD/MM/YYYY</strong></td>
<td><strong>Surname:</strong></td>
</tr>
<tr>
<td><strong>Sex:</strong> Male ☐ Female ☐</td>
<td><strong>DOB:</strong> <strong>DD/MM/YYYY</strong></td>
</tr>
<tr>
<td><strong>Residency:</strong> ☐ SA resident ☐ Non-SA resident ☐ Specifying:</td>
<td><strong>Facility name:</strong></td>
</tr>
<tr>
<td><strong>Current residential address:</strong></td>
<td><strong>Contact number/s:</strong></td>
</tr>
<tr>
<td><strong>Patient’s contact number/s:</strong> <strong>Include alternative number:</strong>____________</td>
<td><strong>Email address:</strong></td>
</tr>
</tbody>
</table>
| **Please indicate occupation (tick all that apply):** ☐ Student | ☐ Unemployed
| ☐ Working with animals | ☐ Health laboratory worker
| ☐ Healthcare worker | ☐ Facility name:
| ☐ Other | ☐ Specify:

**NEXT OF KIN CONTACT DETAILS (alternative contact details)**

| **First name:** | **Surname:** |
| **Relationship to the patient:** | **Contact number(s):** |

**CLINICAL PRESENTATION AND HISTORY**

| **Date of symptom onset:** __DD/MM/YYYY__ | **Date of current consultation/admission:** __DD/MM/YYYY__ |
| **Fever (≥38°C):** ☐ Yes ☐ No | **Sore throat:** ☐ Yes ☐ No
| **History of fever:** ☐ Yes ☐ No | **Mycalgia/body pains:** ☐ Yes ☐ No
| **Cough:** ☐ Yes ☐ No | **Shortness of breath:** ☐ Yes ☐ No
| **Chills:** ☐ Yes ☐ No | **General weakness:** ☐ Yes ☐ No
| **Nausea/vomiting:** ☐ Yes ☐ No | **Intestine/constipation:** ☐ Yes ☐ No
| **Other:** ☐ Yes ☐ No | **Specify______________** |

**DIAGNOSIS**

- Did the patient have clinical or radiological evidence of pneumonia ☐ Yes ☐ No
- Were chest X-rays (CXR) done: ☐ Yes ☐ No
- If Yes, CXR findings: ________________
- Did the patient have clinical or radiological evidence of acute respiratory distress syndrome (ARDS)? ☐ Yes ☐ No
This section is a prerequisite for testing, therefore please fill out the below section to the best of your ability. Laboratory testing will be delayed if forms are incomplete or were filled in incorrectly.

In the 14 days before symptom onset did the patient (mark all that apply):

- [ ] Have close physical contact with a known COVID-19 case?
- [ ] If the patient has been in a close physical contact with a known COVID-19 case, please indicate contact setting:
  - [ ] Healthcare setting
  - [ ] Family setting
  - [ ] Work place
  - [ ] Public transport setting
  - [ ] Other: Specify
- [ ] Patient is a healthcare worker (HCW) who was exposed to patients with severe acute respiratory illness, unless another etiology has been identified to explain the clinical presentation of the HCW?
- [ ] Is the patient part of a severe respiratory illness cluster of unknown etiology that occurred within a 14-day period?
- [ ] Has patient travelled to/from China or area/s with evidence of sustained SARS-CoV-2 (cause of COVID-19) human-to-human transmission, or a declared outbreak?

If patient traveled outside South Africa in the last 14 days, please complete section below for countries visited

<table>
<thead>
<tr>
<th>Country and city or cities visited</th>
<th>Date of departure (travel to area)</th>
<th>Date of return (travel from area)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DD/MM/YYYY</td>
<td>DD/MM/YYYY</td>
</tr>
<tr>
<td>1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

UNDERLYING FACTORS/CO-MORBID CONDITIONS

- [ ] Asthma
- [ ] Cardiac disease
- [ ] Chronic kidney disease
- [ ] Chronic liver disease
- [ ] COPD/Chronic pulmonary disease
- [ ] Diabetes
- [ ] Immuno-deficiency (excluding HIV)
- [ ] HIV
- [ ] Is the patient virally suppressed?
- [ ] Recent viral load:

Other: [ ] Specify

TREATMENT/MANAGEMENT

- [ ] Admitted to ICU
- [ ] Ventilation
- [ ] On ECMO
- [ ] Antibiotics
- [ ] if Yes, list: Tamiflu/other antiviral drugs
- [ ] White cell count total: Neutrophils/Lymphocytes:

Has the patient been isolated at:
- [ ] Home
- [ ] Healthcare facility
- [ ] Not isolated
- [ ] Other: Specify

If patient has been isolated at home or at a healthcare facility, please provide date of isolation: DD/MM/YYYY

OUTCOME (at time of specimen submission)

- [ ] Currently hospitalised
- [ ] Discharged
- [ ] Name of facility:
- [ ] Died
- [ ] Date of death:
- [ ] Other: Specify

If patient is a permanent resident, please provide their current residential address while residing in South Africa. "Close contact" is defined as face-to-face contact or shared room within 1 meter of a COVID-19 case for a total of at least 15 minutes. "Close healthcare workers or other person providing direct care for a COVID-19 case, while not wearing recommended protective equipment (PPE). A contact is an aircraft contact within two rows (fin one row across) of the COVID-19 case. Travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated. Areas with person-to-person transmission of SARS-CoV-2: http://www.modac.co.za/alerts/africa/covid-19/

Please also complete the contact line list provided and submit with specimen submission form and PUI form to pcov@nicd.ac.za
9.9 Appendix 9 – Contact tracing and contact line list
Initial contact with contact of confirmed case

Each individual on the contact line list will be contacted

- Introduce yourself and specify where you are calling from
- Explain the following:
- Someone that tested positive for COVID-19 indicated that they were in close contact with them.
- This means that they are at risk and need to be monitored for 14 days after their exposure to the person to monitor symptoms.
- Ask about the last contact with the case and establish if the person is a close contact. See definition of a close contact in guidelines.
- If person is a close contact, continue with information below. If not, inform person that they have a low risk and should contact their healthcare provider should they develop any symptoms.
- Ask if the person is experiencing any of the listed symptoms on the symptom monitoring tool
  - If yes:
    - A team will visit them at their home to collect a specimen and to issue them with a thermometer
    - Should the test come back positive, they will be treated for COVID-19.
    - Should the test come back negative, we will continue to contact them every day telephonically to monitor their symptoms and should symptoms worsen, we will test them again.
    - This will continue until day 14 after last exposure to the case.
  - If not:
    - A team will visit them at home and issue them with a thermometer.
    - We will contact them every day telephonically to ask if they are experiencing any symptoms.
    - This will continue until day 14 after last exposure to the case.
- During the monitoring period, individuals should self-quarantine at home
  - This means they should not go to work, school, church, shops, visit friends, have friends or non-household members over, etc.
  - If the contact is a healthcare worker that cannot take time of work, they should work with a surgical mask if asymptomatic. If symptomatic, they should self-quarantine.
  - If living with other individuals, the contact and their household members should:
    - Perform hand hygiene frequently, using alcohol-based hand rub if hands are not visibly Soiled or soap and water when hands are visibly soiled;
    - Keep distance from affected individual as much as possible (at least 1 meter);
    - Wear a medical mask when in the same room with the affected individual; replacing mask if damp, dispose of the material immediately after use;
    - Clean hands immediately after contact with respiratory secretions;
    - Improve airflow in living space by opening windows as much as possible.
COVID-19 CONTACT LINE LIST

Complete a contact line list for every person under investigation and every confirmed Coronavirus disease 2019 (COVID-19) case

Details of person under investigation/confirmed COVID-19 case

NICD Identifier
Surname
Contact number
Travelled by

Details of health official completing this form
Surname
Role
Email address

Today’s date
DD/MM/YYYY
Name
Facility name
Telephone number(s)

Air/bus line
Flight/flight
Seat

Details of contacts (With close contact1 from the date of symptom onset, or during symptomatic illness.)

<table>
<thead>
<tr>
<th>Surname</th>
<th>First name(s)</th>
<th>Sex (M/F)</th>
<th>Age (Y)</th>
<th>Relation to case2</th>
<th>Date of last contact with case</th>
<th>Place of last contact with case (Provide name and address)</th>
<th>Residential address (for next month)</th>
<th>Phone number(s), separate by semicolon</th>
<th>HCW? (Y/N)</th>
<th>Facility name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Close contact: A person having had face-to-face contact (2 metres) or was in a closed environment with a COVID-19 case, this includes, amongst others, all persons living in the same household as a COVID-19 case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a COVID-19 case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, N95-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the Index case was seated.

2 Close from: Spouse, Aunt, Child, Class mate, Colleague, Cousin, Father, Friend, Grandfather, Grandmother, Healthcare worker taking care of, Mother, Nephew, Niece, Other relative, Uncle.

HCW?: Healthcare worker
## Details of contacts (With contact from the date of symptom onset, or during symptomatic illness.)

<table>
<thead>
<tr>
<th>Surname</th>
<th>First name(s)</th>
<th>Sex (M/F)</th>
<th>Age (Y)</th>
<th>Relation to case</th>
<th>Date of last contact with case (Provide name and address)</th>
<th>Residential address (for next month)</th>
<th>Phone number(s), separate by semicolon</th>
<th>HCW? (Y/N) if Yes, facility name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DD/MM/YYYY</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Close contact: A person having had face-to-face contact (≤2 metres) or was in a closed environment with a COVID-19 case; this includes, amongst others, all persons living in the same household as a COVID-19 case and, people working closely in the same environment as a case. A healthcare worker or other person providing direct care for a COVID-19 case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated. 2 Chose from: Spouse, Aunt, Child, Classmate, Colleague, Cousin, Father, Friend, Grandfather, Grandmother, Healthcare worker taking care of, Mother, Nephew, Niece, Other relative, Uncle. 3 Healthcare worker.

If more space required, continue on second form. Please complete header and staple to first form.
# 9.10 Appendix 10 – Contact monitoring tool

PDF version at: [http://www.nicd.ac.za/diseases-a-z-index/covid-19/](http://www.nicd.ac.za/diseases-a-z-index/covid-19/)

## COVID-19 DAILY SYMPTOM MONITORING TOOL

Complete for contact of a confirmed Coronavirus disease 2019 (COVID-19) case

<table>
<thead>
<tr>
<th>Details of contact of confirmed case (details of case completed just before instructions)</th>
<th>Details of health official completing this form</th>
<th>Date completing form</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICD identifier</td>
<td>Date of contact</td>
<td>Place last contact</td>
</tr>
<tr>
<td>Surname</td>
<td>DOB/MM/YY</td>
<td>Name</td>
</tr>
<tr>
<td>Date of birth</td>
<td>Age (Y)</td>
<td>Sex</td>
</tr>
<tr>
<td>Healthcare worker</td>
<td>Y □ N □</td>
<td>If yes, facility name</td>
</tr>
<tr>
<td>Contact number(s)</td>
<td>Email</td>
<td>Physical address</td>
</tr>
<tr>
<td>District</td>
<td>Province</td>
<td>Patient traced</td>
</tr>
<tr>
<td>Details of confirmed COVID-19 case</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date (DD/MM)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Instructions for completion:

**Instructions for completion:** Mark “Y” if symptoms present and “N” if not. If any symptoms are present collect contact 082 883 9920 immediately and make immediate arrangements for the collection of a combined nasopharyngeal and oropharyngeal swab. Refer to COVID-19 Quick Guide on the NICD website for additional details. Days post exposure to case.

<table>
<thead>
<tr>
<th>DAY</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measured body temp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chills</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td></td>
</tr>
<tr>
<td>Sore throat</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td></td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td></td>
</tr>
<tr>
<td>Myalgia/body pains</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td>Y N</td>
<td></td>
</tr>
</tbody>
</table>

1 Close contact: A person having had face-to-face contact (1.0 meter) or was in a closed environment with a COVID-19 case. ORS includes, amongst others, all persons living in the same household as a COVID-19 case and people working closely in the same environment as a case. Healthcare worker or other person providing direct care for a COVID-19 case, while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, N95/FFP1-certified disposable PAPR respirator, eye protection). A contact in an aircraft sitting within two seats (in any direction) of the COVID-19 case, travel companions or persons providing care, and crew members serving in the section of the aircraft where the index case was seated. Casual contact: Anyone not meeting the definition for a close contact but with possible exposure. 2 Chose from: Spouse, Aunt, Child, Cousin male, Colleague, Cousin, Father, Friend, Grandfather, Grandmother, Healthcare worker taking care of, Mother, Nephew, Niece, Other relative, Uncle. 3 Diarrhoea defined as three or more loose stools in a 24-hour period. 4
9.11 Appendix 11 – Response to suspected case at port of entry

Standard operating procedure for the management of suspected communicable disease at the points of entry and transportation to a designated hospital

1. INTRODUCTION
Port Health Service (PHS) is defined as the first line of defence to protect the citizens of South Africa and visitors against the health risks associated with cross border movement of people, conveyances, baggage, cargo shipments and other imported consignments. It is thus vital for all points of entry to be on the alert and prepared to respond to a possible importation of a communicable disease, whether intentional or unintentional.

The following standard operating procedures detail measures that must be implemented by Port Health officials in preventing and responding to a suspected case of COVID-19.

2. SCREENING MEASURES

2.1 Screening Procedures

a) Port Health Officials (PHO) must monitor all arriving conveyances from the affected countries and increase surveillance measures.
b) Surveillance measures must be enhanced on conveyances arriving from high risk areas.
c) Upon arrival of the conveyance, PHO must collect and verify the health documentation and interview the crew member/operator to determine if there is any sick passenger on board.
d) In addition to the routine interview of crew members/operators, PHO must ask crew members questions specific to signs and symptoms of COVID-19.
e) PHO must screen all travellers utilising non-invasive thermometer.
f) Travellers with normal temperature may be allowed to proceed.
g) If traveller is found to have a high temperature, he/she must be informed of such and must be assessed further by clinical staff where available.
h) If traveller conforms to the case definition, the suspect case must be transported by emergency medical services to a designated hospital for further management.
i) Where a clinical staff is not available, port health must interview the traveller and if determined to conform to the case definition the traveller must be kept in isolation until such time as emergency medical services transport the traveller to a designated hospital. PHO must inform the NICD and Provincial CDC coordinators.
j) Where thermal scanners are available, all travellers who were not found to have an elevated temperature during the non-invasive thermometer screening must be channelled through the secondary screening utilising a thermal scanner.
k) Travellers found to have elevated temperature must be escorted to the Port Health Clinic where available, for further examination and must be interviewed to determine their travel history.
l) Where Port Health Clinic is not available, Port Health must interview the traveller/s to determine if the traveller/s meet the case definition for PUI.
m) If traveller meets the case definition for PUI COVID-19, the suspect case must be kept in isolation until he/she is transported to a designated hospital for further management (see table below).

Traveller Health Questionnaires

NB! All travellers arriving directly from countries and who have visited China or travellers who had travelled to areas where there is community transmission of COVID-19 in the past 14 days must complete a traveller health questionnaire. All questionnaires must be reviewed in real time analysed and information captured electronically.
Table 2: Hospitals and contact persons for hospitals designated to receive PUI/confirmed cases

<table>
<thead>
<tr>
<th>PROVINCE</th>
<th>2019-nCoV DESIGNATED HOSPITAL NAME</th>
<th>CEO</th>
<th>IPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIMPOPO</td>
<td>Polokwane Hospital</td>
<td>Mr Ramawa: 081 494 6995</td>
<td>Ms Maronel Kruger: 079 978 7984</td>
</tr>
<tr>
<td>MPUMALANGA</td>
<td>Rob Ferreira</td>
<td>S FG Nyathi : 071 682 6396 / 013 741 6307</td>
<td>Ms Francina: 079 365 5522</td>
</tr>
<tr>
<td>GAUTENG</td>
<td>Charlotte Mexeke</td>
<td>Ms Gladys Bogoshi: 082 9273 565</td>
<td>Mr Malebati : 082 332 8501</td>
</tr>
<tr>
<td></td>
<td>Steve Biko Academic Hospital</td>
<td>Dr M Mathebula: 082 907 0973</td>
<td></td>
</tr>
<tr>
<td>KWAZULU-NATAL</td>
<td>Greys Hospital</td>
<td>Dr Ben Bilenge: 083 555 1563</td>
<td>Sr Jennifer Green 074 311 3330</td>
</tr>
<tr>
<td>NORTH WEST</td>
<td>Klerksdorp Hospital</td>
<td>Dr Dikting Mahole: 082 566 1146</td>
<td>Sr Mojaki Mosiatlhaga: 082 450 6116</td>
</tr>
<tr>
<td>FREE STATE</td>
<td>Pelonomi Hospital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NORTHERN CAPE</td>
<td>Kimberley Hospital</td>
<td>Allister Katana: 072 560 9990</td>
<td>S Maritjie Langevelt: 084 467 6888</td>
</tr>
<tr>
<td>EASTERN CAPE</td>
<td>Livingston Hospital</td>
<td>D Makamba: 082 854 1155</td>
<td></td>
</tr>
<tr>
<td>WESTERN CAPE</td>
<td>Tygerberg Hospital</td>
<td>Dr Dimitri Erasmus: 082 455 0824 / 0219384136</td>
<td>Maria Aucamp: 021 938 5065/5054Dr Jantjie: 083 419 1452 / 0219389645Dr Jack Meintjies: 021 938 5563/ 5053/ 5054</td>
</tr>
</tbody>
</table>

3 IN THE EVENT OF PERSON UNDER INVESTIGATION ONBOARD THE CONVEYANCE

3.1 Prior to arrival of conveyance

a) If traveller presents with symptoms related to a communicable disease while on board a conveyance;
   - In case of airport/sea port the tower/captain will inform Operations/Agent who must inform PHO of the ill passenger,
   - In case of land port, PHO will be informed on arrival of the conveyance at the port.

b) Suspected case is moved to an isolated area on the conveyance, if sufficient space is available.

c) Nurse or PHO must contact the NICD to confirm whether the symptoms meet the 2019-nCoV PUI case definition;

d) Based on the information provided, Port Health must notify and make arrangements with the designated health facilities and ambulance for transportation of the ill traveller.

e) Port Health must then notify the relevant Provincial Communicable Disease Control Coordinator.

3.2 Once the conveyance has arrived at the Point of Entry

a) PHO must board the conveyance, together with the clinical personnel and ensure entrance to the conveyance is secured and no person enters or leaves the conveyance.

b) PHO must obtain and confirm the following information from the crew member:
- number of cases,
- signs and symptoms;
- vector control measures, where required and
- collect and verify the required health documentation and passenger list;

c) PHO must brief the passengers that there is a possible case of COVID-19 on board, calm them and provide the necessary health information, including, reporting to the nearest health facility and inform the health worker of their travel history should they experience any symptoms;

d) PHO must identify the contacts and allow all passengers except the sick passenger and contacts to disembark;

e) Sick passenger may then be escorted from the aircraft and transported to the designated health facility (see section 5 below: Medical Evacuation Procedure);

f) Passenger locator cards and health information must be handed out to the contacts and inform them that they will be contacted for monitoring purposes;

g) Contacts may then be allowed to disembark and channelled through thermal screening processes.

h) Port Health must hand over passenger list and close contact details to Provincial Communicable Disease Control Coordinator (contact details in table below) for further monitoring;

i) The ground handling and cleaning company of the conveyance operators should be notified at the same time so that preparations can be made for appropriate cleaning and/or disinfection of the conveyance after passengers have disembarked; if required;

j) PHO must monitor the entire cleaning and/or disinfection process.

Table 3: Contact details of Communicable Diseases control coordinators

<table>
<thead>
<tr>
<th>Province</th>
<th>CDC coordinator</th>
<th>Contact number/s</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECP</td>
<td>Mr. T Dlamini, Ms. N Mgobo</td>
<td>083 378 0189, 060 579 9027</td>
</tr>
<tr>
<td>FSP</td>
<td>Ms. B Nyokong, Ms. D Baleni</td>
<td>083 757 8217/051 408 1734, 082 463 7499</td>
</tr>
<tr>
<td>GP</td>
<td>Dr. Asomugha, Ms. C Kesebilwe</td>
<td>082 330 1490, 083 490 8165 / 011 355 3867</td>
</tr>
<tr>
<td>KZN</td>
<td>Ms. P Govender</td>
<td>071 609 2505</td>
</tr>
<tr>
<td>LP</td>
<td>Ms. M.F. Ngobeni, Ms. M.P. Mudau</td>
<td>079 491 1909 / 015 293 6062, 071 678 3864</td>
</tr>
<tr>
<td>MP</td>
<td>Mr M Zwane, Ms. H Mpangane</td>
<td>082 229 8893 / 013 766 3078, 076 522 8511 / 013 766 3411</td>
</tr>
<tr>
<td>NCP</td>
<td>Ms. Gloria Hottie</td>
<td>072 391 3345 / 053 830 0529</td>
</tr>
<tr>
<td>NWP</td>
<td>Ms C Lebeko</td>
<td>082 421 7985 / 018 397 2600</td>
</tr>
<tr>
<td>WCP</td>
<td>Ms C Lawrence</td>
<td>072 356 5146 / 021 483 9964</td>
</tr>
</tbody>
</table>

4 MANAGEMENT OF INTENTIONAL TRANSPORTATION OF A SICK PASSENGER INTO SOUTH AFRICA/CONFIRMED CASE

a) Conveyance operators or medical companies transporting patients to South Africa for medical attention by commercial flight, charter flight or road ambulances must notify PHO beforehand utilising notification Form AC1 and include the medical history of the patient.

b) Form AC2 must be completed by the medical crew for information on the symptoms of the patient.

c) For patients arriving from the affected countries, Port Health must consult with the NICD and the Chief Director: Environmental Health & Port Health Services before a decision is taken to approve or disapprove the transportation of the patient.

d) If approval to transport the patient is granted, PHO must issue Form PH1 to the applicant.
e) In instances where a patient develops symptoms related to a communicable disease before or during transportation, the AC2 form must be completed and handed over to the PHO upon arrival at the airport.

f) Port Health Officials and Port Health Nurse must assess the patient upon arrival and inform the hospital receiving the patient of the condition.

g) All information related to the passenger must be communicated to the Provincial CDC and NICD to conduct a follow-up on the case.

h) Port Health Official or Port Health Nurse must follow up with the hospital to receive an update prior to closing the file.

i) Port Health Officials (PHO) must monitor all arriving conveyances from the affected countries and increase surveillance measures.

j) Upon arrival of the conveyance, Port Health Officials must collect and verify the health documentation and interview the crew member/operator to determine if there is any sick passenger on board.

k) In addition to the routine interview of crew members/operators, Port Health Officials must ask crew members questions specific to signs and symptoms of COVID-19.

l) If PHO is certain that there are no sick passengers on board and all health requirements have been met, the passengers may be allowed to disembark.

m) All arriving travellers must be channelled through the thermal scanning processes.

n) Travellers found to have elevated temperature must be escorted to the Port Health clinic where available, for further examination and must be interviewed to determine their travel history.

o) Where Port Health Clinic is not available, Port Health must interview the traveller with elevated temperature to determine their travel history, record the details of the traveller and if required transfer the traveller to the nearest health facility.

p) Travellers presenting with any one of these symptoms; fever, cough, headache, joint and muscle aches, sore throat, and weakness, diarrhoea, vomiting, stomach pain and have travelled to the affected countries must be isolated and arrangements be made for transportation of the traveller to the nearest designated health facility for further management.

5 MEDICAL EVACUATION PROCEDURE

This section is referenced from the STANDARD OPERATING PROCEDURE FOR THE RECOGNITION AND MANAGEMENT OF A SUSPECTED OR CONFIRMED NOVEL CORONAVIRUS PATIENT. The SOP can be accessed from: http://www.health.gov.za/index.php/shortcodes/2015-03-29-10-42-47/2015-04-30-08-29-27/2015-04-30-08-33-30

1.1 Suspected/Confirmed COVID-19 medical evacuation procedure

- The provincial Emergency management Services (EMS) manager must be contacted when an ambulance is requested to transfer a suspected or confirmed COVID-19 patient to and from a designated/referral hospital. (Annexure 8: Provincial EMS Managers’ contact details)

- The Provincial CDC must be informed prior to EMS medical evacuation of any suspected/confirmed 2019-nCoV patient.

- Driver must not have any contact with patient and must act as liaison

- Ideally two trained EMS specialized response team personnel must accompany patient.

- Hand hygiene must be observed before and after every contact with patient.

- Don correct PPE.

- Focus of care is supportive and maintaining existing treatment. No invasive procedures should be done in transit. (No sharps to be used)

- Keep contact with designated referral hospital. Determine and communicate an estimated time of arrival (ETA) and report an update on patient’s condition, as hospital needs to prepare: - isolation ward needs to be prepared, staff need to don PPE, security needs to clear public and staff from entrance and route.
When arriving at hospital, the patient is to be kept inside ambulance until hospital indicates that the patient is allowed to enter.

Provincial CDC must be informed after every COVID-19 transfer; crew must be placed on 14-day contact list and must submit temperature readings twice a day.

1.2 Unsuspected COVID-19 EMS medical evacuation procedure

- Normal call out to a home or healthcare facility and/or after transporting has commenced, a suspicion for a possible COVID-19 case is raised.
- Immediately contact and report to Provincial CDC who will assist in advice and decision on where to take patient.
- Driver must not have any contact with patient and must act as liaison.
- Hand hygiene must be observed before and after every contact with patient.
- EMS personnel must Don correct PPE.
- Focus of care is supportive and maintaining existing treatment. No invasive procedures should be done in transit. (No sharps to be used)
- Keep contact with designated referral hospital. Determine and communicate an estimated time of arrival (ETA) and report an update on patient’s condition, as hospital needs to prepare: - isolation ward needs to be prepared, staff need to don PPE, security needs to clear public and staff from entrance and route.
- When arriving at hospital, the patient is to be kept inside ambulance until hospital indicates that the patient is allowed to enter.
- Provincial CDC must be informed after every COVID-19 transfer, crew must be placed on 14-day contact list and must submit temperature readings twice a day.

1.3 Medical evacuation procedure of COVID-19 patient to and from a Healthcare facility

- When arriving at the healthcare facility, the patient and clinical team will remain inside the ambulance or isolation ward. The driver will liaise with healthcare staff and only after the indication from healthcare staff has been given that they are ready to receive/transfer the patient, can the patient be taken to/from the ambulance/isolation ward.
- Driver must ensure that healthcare facility is ready to receive or transfer the patient and that public are cleared from entrance and route that patient will be moved along.
- During the movement of the patient, ensure that all spills are immediately cleaned and decontaminated on the route that patient was moved.

1.4 Cleaning and decontamination

- Crew decontaminating the ambulance should wear correct PPE.
- During or after transport of a COVID-19 patient, vomitus, blood and other spillages should be flooded with disinfectant, namely chlorine solution with a concentration of 5000 ppm (0.5%) or 20x30g sachets of Biocide D Extra/10L water, covered with paper towels or absorbent material and left for at least 30 minutes before cleaning.
- Never use high pressure jet spray inside confined space of ambulance.
- Physical material like blood and vomitus must first be cleaned up and removed before terminal cleaning can start.
- All surfaces should be wiped down and washed at least two times, with 500 ppm (0.05%) chlorine solution. Vehicle is ready to use again immediately after cleaning.
- Containers with secretions, excretions and other waste products such as vomitus and blood should be flooded with a copious amount of disinfectant, namely chlorine solution with a concentration of 5000 ppm (0.5%) or 20x30g sachets of Biocide D Extra/10L water, for at least 30 minutes.
- All items leaving the ambulance should be enclosed and sealed in adequate layers of appropriate bags to prevent leakage. The outer surfaces of the bags should be wiped with chlorine disinfectant at a concentration of 0.05% (500 ppm) and labelled as bio hazardous. Disposable equipment should be
disposed of by incineration (as per normal Health Care Waste Management (HCWM) Regulation Act 59, 2008), non-disposable equipment can be washed and disinfected (Autoclaved).

• If sharps bin, for any reason, was used it needs to be wiped down and placed inside plastic bag. Bag is wiped again and placed inside double red bag and sealed in waste box that should then be clearly marked as containing sharps.

1.5 Handling of Health care waste

• As per normal HCWM Regulation, ensure that waste is safely stored until the health care waste management company can pick it up. Ensure that the company knows and acknowledges that waste was generated by suspected or confirmed COVID-19 case.
• All bags, bins and boxes must be adequately sealed, as not to leak any fluids, and must be wiped down with 0.05% chlorine solution before being stored or removed.

1.6 Handling of Suspected or Confirmed COVID-19 case mortal remains.

• If patient dies in transit, the EMS Provincial coordinator and Provincial CDC must be notified. A decision on where to take the corpse must be communicated to the ambulance crew.
• Provincial Environmental Health must be informed.
• Under no circumstances will the corpse be removed from ambulance other than at assigned facility that was communicated to ambulance crew.
• The corpse must be placed in double body bags that are fluid leak proof. The bags must be wiped down with a 0.05% chlorine solution before leaving the ambulance.
• The removal of a suspected COVID-19 corpse must be done under the directive of Environmental Health.
Annexure 11.1:
Flow diagram depicting the approach to an imported PUI/suspected or confirmed case of infectious disease at port of entry (PoE)

**Suspected Case from an Incoming Conveyance**

- Patient or other passengers informs flight attendant who informs conveyance operator
- Crew moves suspected patient to isolated area
- Suspected patient is given a facemask to put on

**Confirmed Case/Intentional transportation**

- Evacuation/airline Company informs PHO prior to transfer of case

**Tower/Agent informs Port Health Officer (PHO)**

**PHO informs NICD of suspected case**

- PHO contacts emergency medical Services (EMS) and designated hospital for patient referral

**Port Health Officer notifies Provincial Communicable Disease Control Coordinator (CDC)**

- Upon arrival of conveyance, PHO facilitates assessment of passenger and contacts on the conveyance prior to their disembarkation

**PHO identifies all close contacts, facilitates completion of passenger locator cards and allows contacts to disembark**

**CDC coordinator monitors contacts utilising information provided by port health**

- Where cleaning and/or disinfection is required, PHO must inform the cleaning/ground handling company and monitor the process

**Evacuation/airline Company informs PHO prior to transfer of case**

**PHO informs NICD and the Regional Port Health Director about the request and takes a decision**

**Following acceptance, PHO communicates decision to medical company**

**Upon arrival of conveyance, PHO and Nurse must assess the patient and inform receiving hospital**

**PHO must communicate passenger information to Provincial Communicable Disease Control**
Annexure 11.2:

The flow diagram depicts the process flow for the management of a suspected or possible case from a country/area reporting outbreak of contagious infectious disease.

**Incoming Vessel**
- Patient or other passengers informs captain/crew
- Crew moves suspected patient to isolated area
- Captain reports illness to Harbour

**Incoming Road/Rail**
- Traveller informs driver/port health on arrival

**Captain or clearing agent informs Port Health Officer (PHO)**

**PHO contacts Emergency Medical Services (EMS) and designated hospital for patient referral and notifies Provincial/District CDC**

**PHO facilitates assessment of passenger and contacts on the vessel prior to their departure from the harbour**

**CDC coordinator monitors contacts utilising information provided by Port Health**

**If close contacts develop signs and symptoms, refer to designated health facility**

**Where cleaning and/or disinfection is required, PHO must inform the cleaning/handling company and monitor the process**
9.12 **Appendix 12 – Guidelines for the safe handling of human remains of confirmed/suspected COVID-19 case and repatriation of human remains of confirmed/suspected COVID-19 case**

- The human remains of a person who has died of a confirmed COVID-19 should be cremated.
- Where cremation is not possible, the repatriation of human remains who died of confirmed/suspected COVID-19 must be conducted in line with the Regulations Relating to the Management of Human Remains (Regulation 363 of 22 May 2013).
- A formal request for an import/export permit issued by the Director-General: Health must be made by the Department of International Relations and Cooperation (DIRCO) or through the embassies, prior to importation/exportation of the human remains.
- Once a permit has been issued by the Director-General, the human remains may be transported.
- The human remains must not be embalmed and shall be transported under the following precautions:
  - Be placed in leak proof triple body bag and in a non-transparent sealed coffin,
  - The first two body bags must be transparent and sealed and the third body bag non-transparent and not sealed
  - After the body has been placed in the triple body bag, the remains must be placed in a non-transparent coffin which is lined with 5cm saw dust to prevent any potential leakages.
- The import/export permit, death certificate and written declaration by an institution responsible for packaging the human remains that transportation of human remains will not constitute a health hazard must accompany the human remains at all times.
- No person must open the coffin or remove the human remains after they have been sealed without prior approval from an Environmental Health Practitioner.

**In the case of importation:**

- Environmental Health Practitioner (EHP) at a point of entry must inform forensic pathology of the arrival of the human remains for transportation to a mortuary of the designated hospital.
- EHP at a point of entry must monitor the removal of the remains from the conveyance to the forensic pathology vehicle.
- EHP at a Municipal level must monitor the handling of the human remains after arrival at the designated mortuary.
In the case of exportation;

- The human remains must be transported from the mortuary of a designated hospital to the point of entry by Forensic Pathology in consultation with the embassy of which the deceased holds residence.
- EHP at a Municipal level must monitor the handling of the human remains at the designated mortuary.
- EHP at a point of entry must monitor the removal of the human remains from the forensic pathology vehicle to the conveyance.

Management (handling, movement, storage and burial) of human remains of a person who died of COVID-19

- Handling of the Human Remains must be strictly monitored by EHP throughout the process.
- Human remains shall be placed in a leak proof triple body bag both first two bags shall be transparent and sealed while the third one shall be non-transparent and unsealed.
- After the body has been placed in the triple body bag, the remains must be placed in a non-transparent coffin.
- The human remains must be transported in a manner that is in compliant with the provisions of the Regulations Relating to the Management of Human Remains.
- The Human remains are considered contagious and should be kept only in designated health facilities’ mortuaries.
- Human Remains can only be transferred from one designated facility to another designated facility or from such to a cemetery or crematorium.
- Under no circumstances shall the human remains be directly handled, whether for aesthetic, hygiene preparations, cultural or religious reasons.
- The human remains may not be embalmed or viewed by breaking the seals of first two bags but by opening the third bag.
- Where it is feasible and acceptable to family culture and/or religion, it is strongly recommended that the remains be cremated.
- In all cases, remains should not be kept in households for vigil or any purpose but be kept in designated health facility mortuary premises and directly transported from designated health facility mortuary straight to place of burial or cremation or the home on the day of burial/cremation.
- The body should be buried in a sufficiently deep grave to prevent access by rodents and carnivores.
- Human remains shall be placed in a triple body bag both first two bags shall be transparent and sealed while the third one shall be non-transparent and unsealed zip-up body bag with handles and appropriate BIOHARZARD warning tag written “hazard Group 4 Pathogens” before transporting to designated health facility mortuary.
• All bags, bins and boxes must be adequately sealed, as not to leak any fluids, and must be wiped down with 0.05% chlorine solution before being stored or removed.

1.7 Handling of Suspected or Confirmed COVID-19 case mortal remains.
• If patient dies in transit, the EMS Provincial coordinator and Provincial CDC must be notified. A decision on where to take the corpse must be communicated to the ambulance crew.
• Provincial Environmental Health must be informed.
• Under no circumstances will the corpse be removed from ambulance other than at assigned facility that was communicated to ambulance crew.
• The corpse must be placed in double body bags that are fluid leak proof. The bags must be wiped down with a 0.05% chlorine solution before leaving the ambulance.
9.13 Appendix 13 – Communicable Diseases Outbreak Report Format

<table>
<thead>
<tr>
<th>TITLE</th>
<th>PERIOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOCATION</td>
<td>DISTRICT</td>
</tr>
<tr>
<td>PROVINCE</td>
<td></td>
</tr>
</tbody>
</table>

Executive summary

I. Introduction:
- Background
- Reasons for investigation (public health significance, threshold met, etc.)
- Investigation and outbreak preparedness

II. Methods:
- Dates of investigation
- Site(s) of investigation (health care facilities, villages, other)
- Case finding (indicate what was done regarding case finding, e.g., register review, contact investigation, alerting other health facilities, other)
- Lab specimen collection
- Description of response and intervention (include dates)
- Data management

III. Results:
- Date and location of first known (index) case
- Date and health facility where first case was seen by the health care system
- Results of additional case finding
- Lab analysis and results
- With text, describe key features of results of time, place, and person analysis
- For detailed results by time (epi curve), place (map), and person characteristics (tables) and line lists
- Results of response and evidence of impact

IV. Self-evaluation of the timeliness and quality of preparedness, outbreak detection, investigation, and response
### Epidemic Preparedness

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were adequate medical supplies available at the onset of the outbreak</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Were clinical guidelines available to health workers?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the district epidemic management committee regularly meet as part of epidemic preparedness?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Outbreak Detection

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Date 1</th>
<th>Date 2</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval between onset of index case (or occurrence of an unusual cluster at the community level) [date 1] to arrival of first outbreak case at the health facility [date 2] (Target: &lt;3 days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval between initial outbreak case seen at the health facility [date 1] and reporting to the district health team [date 2] (Target: within 24 hours)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cumulative interval between onset of index case (or occurrence of an unusual cluster at the community or health facility) [date 1] to notification to the district [date 2] (Target: &lt;7 days)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Outbreak investigation

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Were case forms and line lists completed?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Were laboratory specimens taken (if required)?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Date 1</th>
<th>Date 2</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval between notification of district [date 1] and district field investigation conducted [date 2] (Target: within 48 hours)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval between sending specimens to the lab [date 1] and receipt of results by the district [date 2] (Target: 3-7 days, depending on type of test)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Outbreak response:

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Date 1</th>
<th>Date 2</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval between notification of outbreak to district [date 1] and concrete response by the district [date 2] (Target: within 48 hours of notification)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Evaluation and Feedback:

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Date 1</th>
<th>Date 2</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interval between end of the outbreak [date 1] and finalization of outbreak report with case forms/line list sent to national level [date 2] (Target: 2 weeks)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Did the outbreak management committee meet to review investigation results?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Was feedback given to health facilities and community?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
V. Evaluation of other aspects of the response:

.................................................................................................................................. ..................................
..............................................................................................................................................................

VI. Interpretations, discussion, and conclusions:

.......................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................

VII. Recommended public health actions:

Comment on following levels: community, health facility, district, partners, provincial, and national

........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................
........................................................................................................................................................................

District Epidemic Committee Chairperson:

Name:  _____________________________________________________
Signature: ___________________________________________________
Date report completed: ________________________________________
### 9.14 Appendix 14 – Contact details (email address and telephone) of stakeholders involved in supporting outbreak response.

<table>
<thead>
<tr>
<th>Institution/Province</th>
<th>Name</th>
<th>Email address</th>
<th>Telephone number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National Department of Health</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communicable Disease Control</td>
<td>Tsakani Furumele</td>
<td><a href="mailto:Tsakani.Furumele@health.gov.za">Tsakani.Furumele@health.gov.za</a></td>
<td>012 395 8096 / 0824199686</td>
</tr>
<tr>
<td>Malaria, Vector-borne and Zoonotic Diseases</td>
<td>Devanand Moonasar</td>
<td><a href="mailto:Patric.Moonasar@health.gov.za">Patric.Moonasar@health.gov.za</a></td>
<td>082 578 3107</td>
</tr>
<tr>
<td></td>
<td>Wayne Ramkrishna</td>
<td><a href="mailto:Wayne.Ramkrishna@health.gov.za">Wayne.Ramkrishna@health.gov.za</a></td>
<td>082 317 4687</td>
</tr>
<tr>
<td>Port Health</td>
<td>Funeka Bongweni</td>
<td><a href="mailto:Funeka.Bongweni@health.gov.za">Funeka.Bongweni@health.gov.za</a></td>
<td>012 395 9728 / 0609930107</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>Murdock Ramathuba</td>
<td><a href="mailto:Murdock.Ramathuba@health.gov.za">Murdock.Ramathuba@health.gov.za</a></td>
<td>012 395 8518 / 0814150093</td>
</tr>
<tr>
<td>Emergency Medical Services</td>
<td>Raveen Naidoo</td>
<td><a href="mailto:Raveen.Naidoo@health.gov.za">Raveen.Naidoo@health.gov.za</a></td>
<td>012 395 821</td>
</tr>
<tr>
<td></td>
<td>Ahmed Bham</td>
<td><a href="mailto:Ahmed.Bham@health.gov.za">Ahmed.Bham@health.gov.za</a></td>
<td>012 395 9636 / 0735716392</td>
</tr>
<tr>
<td>Hospital Services</td>
<td>Keneilwe Modise</td>
<td><a href="mailto:Keneilwe.Modise@health.gov.za">Keneilwe.Modise@health.gov.za</a></td>
<td>012 395 8257 / 0829648888</td>
</tr>
<tr>
<td>Infection Prevention and Control</td>
<td>Ronel Steinhobel</td>
<td><a href="mailto:Ronel.Steinhobel@health.gov.za">Ronel.Steinhobel@health.gov.za</a></td>
<td>012 395 9198 / 0836275661</td>
</tr>
<tr>
<td><strong>Provincial Communicable Disease Control Directorate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eastern Cape</td>
<td>Thomas Dlamini</td>
<td><a href="mailto:thomas.dlamini@echhealth.gov.za">thomas.dlamini@echhealth.gov.za</a></td>
<td>083 378 0189</td>
</tr>
<tr>
<td></td>
<td>Dikeledi Baleni</td>
<td><a href="mailto:balenid@fshealth.gov.za">balenid@fshealth.gov.za</a></td>
<td>083 757 8217</td>
</tr>
<tr>
<td></td>
<td>Babsy Nyokong</td>
<td><a href="mailto:nyokongb@fshealth.gov.za">nyokongb@fshealth.gov.za</a></td>
<td>082 463 7499</td>
</tr>
<tr>
<td>Gauteng</td>
<td>Chika Asomugha</td>
<td><a href="mailto:Chika.Asomugha@gauteng.gov.za">Chika.Asomugha@gauteng.gov.za</a></td>
<td>082 330 1490</td>
</tr>
<tr>
<td></td>
<td>Caroline Kesebilwe</td>
<td><a href="mailto:Caroline.kesebilwe@gauteng.gov.za">Caroline.kesebilwe@gauteng.gov.za</a></td>
<td>083 490 8165</td>
</tr>
<tr>
<td>KwaZulu-Natal</td>
<td>Premi Govender</td>
<td><a href="mailto:premi.govender@kznhealth.gov.za">premi.govender@kznhealth.gov.za</a></td>
<td>071 609 2505</td>
</tr>
<tr>
<td>Limpopo</td>
<td>Marlene Freda Ngobeni</td>
<td><a href="mailto:Marlene.Ngobeni@dhsd.limpopo.gov.za">Marlene.Ngobeni@dhsd.limpopo.gov.za</a></td>
<td>079 491 1909</td>
</tr>
<tr>
<td>Province</td>
<td>City</td>
<td>Contact Person</td>
<td>Email</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Mpumalanga</td>
<td></td>
<td>Mashudu P. Mudau</td>
<td><a href="mailto:Prudance.Mudau@dhsd.limpopo.gov.za">Prudance.Mudau@dhsd.limpopo.gov.za</a></td>
</tr>
<tr>
<td></td>
<td>Mpumalanga</td>
<td>Mandla Zwane</td>
<td><a href="mailto:MandlaZw@mpuhealth.gov.za">MandlaZw@mpuhealth.gov.za</a></td>
</tr>
<tr>
<td></td>
<td>Mpumalanga</td>
<td>Hluphi Mpangane</td>
<td><a href="mailto:hluphim@mpuhealth.gov.za">hluphim@mpuhealth.gov.za</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North West</td>
<td></td>
<td>Chriseldah Leboko</td>
<td><a href="mailto:clebeko@nwpg.gov.za">clebeko@nwpg.gov.za</a></td>
</tr>
<tr>
<td>Northern Cape</td>
<td></td>
<td>Gloria Hottie</td>
<td><a href="mailto:hottieg@webmail.co.za">hottieg@webmail.co.za</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Cape</td>
<td></td>
<td>Charlene Jacobs</td>
<td><a href="mailto:Charlene.Jacobs@westerncape.gov.za">Charlene.Jacobs@westerncape.gov.za</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Port Health and Environmental Health</td>
<td>Funeka Bongweni</td>
<td><a href="mailto:Funeka.Bongweni@health.gov.za">Funeka.Bongweni@health.gov.za</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ockert Jacobs</td>
<td><a href="mailto:Ockert.Jacobs@health.gov.za">Ockert.Jacobs@health.gov.za</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coastal Region</td>
<td></td>
<td>Antoinette Hargreaves</td>
<td><a href="mailto:Antoinette.Hargreaves@health.gov.za">Antoinette.Hargreaves@health.gov.za</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency Medical Services (EMS)- see table below</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Institute for Communicable Diseases (NICD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hotline (24-hours)</td>
<td>Doctor-on-call</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deputy Incident Manager</td>
<td>Ann Mathews</td>
<td><a href="mailto:annm@nicd.ac.za">annm@nicd.ac.za</a></td>
<td></td>
</tr>
<tr>
<td>Laboratory</td>
<td>Anne von Gottberg</td>
<td><a href="mailto:annev@nicd.ac.za">annev@nicd.ac.za</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nicole Wolter</td>
<td><a href="mailto:nicolew@nicd.ac.za">nicolew@nicd.ac.za</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jinal Bhiman</td>
<td><a href="mailto:jinalb@nicd.ac.za">jinalb@nicd.ac.za</a></td>
<td></td>
</tr>
<tr>
<td>Case Management</td>
<td>Kerrigan McCarthy</td>
<td><a href="mailto:kerriganm@nicd.ac.za">kerriganm@nicd.ac.za</a></td>
<td></td>
</tr>
</tbody>
</table>
Epidemiology and Surveillance  | Sibongile Walaza | sibongilew@nicd.ac.za | 083 657 4741  
| Jackie Kleynhans | jackiek@nicd.ac.za |  
| Genevie Ntshoe | genevien@nicd.ac.za |  

**Designated Hospitals**  
**Eastern Cape:** Livingston Hospital  | 041 405 2255  
**Free State:** Pelonomi Hospital  | 051 405 1911  
**Gauteng:**  
Charlotte Maxeke Johannesburg Academic Hospital  | 011 717 1000  
Steve Biko Academic Hospital  | 012 354 1000  
**KwaZulu-Natal:** Greys Hospital  | 033 897 3000  
**Limpopo:**  
Polokwane Hospital  | 015 287 5000  
**Mpumalanga:**  
Rob Ferreira Hospital  | 013 741 6100  
**North West:**  
Klerksdorp Hospital  | 018 406 4600  
**Northern Cape:**  
Kimberley Hospital  | 053 802 9111  
**Western Cape:**  
Tygerberg Hospital  | 021 938 5454
### Provincial EMS Managers

<table>
<thead>
<tr>
<th>PROVINCE</th>
<th>Contact Details</th>
<th>Contact Persons</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>National Department of Health: EMS &amp; Disaster Medicine Directorate</strong></td>
<td>012 395 9636 / 081 324 4555</td>
<td>Mr Raveen Naidoo (Director)</td>
</tr>
<tr>
<td></td>
<td>012395 9636 / 073 571 6392</td>
<td>Mr Ahmed Bham ( EMS Operational Manager – Disaster Medicine )</td>
</tr>
<tr>
<td><strong>Gauteng</strong></td>
<td>011 564 2211 / 072 433 7450</td>
<td>Mr. J.P. Von Benecke</td>
</tr>
<tr>
<td></td>
<td>011 564 2021</td>
<td>Mr Kgati Malebane ( Director EMS)</td>
</tr>
<tr>
<td><strong>Western Cape</strong></td>
<td>012 937 0300</td>
<td>Mr. Arthur van Heerden</td>
</tr>
<tr>
<td></td>
<td>082 568 6489 / 021 948 9908</td>
<td>Dr S De Vries ( Director EMS)</td>
</tr>
<tr>
<td><strong>Kwazulu Natal</strong></td>
<td>0834571242</td>
<td>Mr M Mabaso</td>
</tr>
<tr>
<td></td>
<td>083 501 1955 / 033 846 7237</td>
<td>Ms B Zungu ( Director EMS)</td>
</tr>
<tr>
<td><strong>Free State</strong></td>
<td>0609856082</td>
<td>Mr R Ruiters (Provincial EMS Ops Manager)</td>
</tr>
<tr>
<td></td>
<td>082 659 1600 / 051 408 1855</td>
<td>Dr Joe Khoali ( Director EMS)</td>
</tr>
<tr>
<td><strong>North West</strong></td>
<td>082 335 6034 / 018 473 0324</td>
<td>Mr B Redlinghys ( Director EMS)</td>
</tr>
<tr>
<td><strong>Limpopo</strong></td>
<td>082 040 5494</td>
<td>Mr F Masegela</td>
</tr>
<tr>
<td></td>
<td>082 440 0802 / 015 295 2999</td>
<td>Dr Clive Sibanda ( Director EMS)</td>
</tr>
<tr>
<td><strong>Northern Cape</strong></td>
<td>053 802 2280 / 053 831 1954/5</td>
<td>Mr R. Dreyer</td>
</tr>
<tr>
<td></td>
<td>083 335 6034 / 053 831 2884</td>
<td>Mr M Ntintelo ( Director EMS)</td>
</tr>
<tr>
<td><strong>Mpumalanga</strong></td>
<td>013 753 2288/ 082 907 3256</td>
<td>Mr. Scosh Mkhonto</td>
</tr>
<tr>
<td></td>
<td>013 766 3302 / 082 828 6223</td>
<td>Mr Zungu ( Director EMS)</td>
</tr>
<tr>
<td><strong>Eastern Cape</strong></td>
<td>060 572 9172 / 060 572 9172</td>
<td>Mr AK Munilil ( Director EMS)</td>
</tr>
</tbody>
</table>